Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance. by Taylor-Robinson, DC et al.
Deworming drugs for treating soil-transmitted intestinal
worms in children: effects on growth and school performance
(Review)
Taylor-Robinson DC, Jones AP, Garner P
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2008, Issue 2
http://www.thecochranelibrary.com
1Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
T A B L E O F C O N T E N T S
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW . . . . . . . . . . . . . . . . . .
4SEARCH METHODS FOR IDENTIFICATION OF STUDIES . . . . . . . . . . . . . . . . . . .
4METHODS OF THE REVIEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5DESCRIPTION OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODOLOGICAL QUALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12POTENTIAL CONFLICT OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . .
12ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
17Characteristics of included studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37Characteristics of excluded studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
38Characteristics of ongoing studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39Table 01. Community diagnosis categories and recommended treatment strategies (WHO 2002) . . . . . . .
40Table 02. Detailed search strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41Table 03. Cluster-randomized controlled trials . . . . . . . . . . . . . . . . . . . . . . . . .
42Table 04. Trials with incomplete statistical data sets . . . . . . . . . . . . . . . . . . . . . . .
48Table 05. Methodological quality assessment . . . . . . . . . . . . . . . . . . . . . . . . .
50Table 06. Trials evaluating school performance or cognition . . . . . . . . . . . . . . . . . . . .
53ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
53Comparison 01. Single dose: change in value . . . . . . . . . . . . . . . . . . . . . . . . .
53Comparison 02. Single dose: end value . . . . . . . . . . . . . . . . . . . . . . . . . . .
53Comparison 03. Multiple dose < 1 year: change in value . . . . . . . . . . . . . . . . . . . . .
53Comparison 04. Multiple dose < 1 year: end value . . . . . . . . . . . . . . . . . . . . . . .
54Comparison 05. Multiple dose > 1 year: change in value . . . . . . . . . . . . . . . . . . . . .
54Comparison 06. Multiple dose > 1 year: end value . . . . . . . . . . . . . . . . . . . . . . .
54Comparison 07. Analysis by worm prevalence or intensity . . . . . . . . . . . . . . . . . . . . .
54Comparison 08. Subgroup and sensitivity analyses . . . . . . . . . . . . . . . . . . . . . . .
55INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55COVER SHEET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56GRAPHS AND OTHER TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56Analysis 01.01. Comparison 01 Single dose: change in value, Outcome 01 Weight (kg) . . . . . . . . . . .
57Analysis 01.02. Comparison 01 Single dose: change in value, Outcome 02 Height (cm) . . . . . . . . . .
58Analysis 01.03. Comparison 01 Single dose: change in value, Outcome 03 Mid-upper arm circumference (cm) . .
59Analysis 01.04. Comparison 01 Single dose: change in value, Outcome 04 Triceps skin fold (mm) . . . . . . .
59Analysis 01.05. Comparison 01 Single dose: change in value, Outcome 05 Subscapular skin fold (mm) . . . . .
60Analysis 01.06. Comparison 01 Single dose: change in value, Outcome 06 Haemoglobin (g/dL) . . . . . . .
60Analysis 02.01. Comparison 02 Single dose: end value, Outcome 01 Weight (kg) . . . . . . . . . . . . .
62Analysis 02.02. Comparison 02 Single dose: end value, Outcome 02 Height (cm) . . . . . . . . . . . .
63Analysis 02.03. Comparison 02 Single dose: end value, Outcome 03 Mid-upper arm circumference (cm) . . . .
64Analysis 02.04. Comparison 02 Single dose: end value, Outcome 04 Triceps skin fold (mm) . . . . . . . . .
64Analysis 02.05. Comparison 02 Single dose: end value, Outcome 05 Subscapular skin fold (mm) . . . . . . .
65Analysis 02.06. Comparison 02 Single dose: end value, Outcome 06 Body mass index . . . . . . . . . . .
iDeworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
65Analysis 02.07. Comparison 02 Single dose: end value, Outcome 07 Haemoglobin (g/L) . . . . . . . . . .
66Analysis 02.08. Comparison 02 Single dose: end value, Outcome 08 Harvard Step Test . . . . . . . . . . .
66Analysis 03.01. Comparison 03 Multiple dose < 1 year: change in value, Outcome 01 Weight (kg) . . . . . . .
67Analysis 03.02. Comparison 03 Multiple dose < 1 year: change in value, Outcome 02 Height (cm) . . . . . . .
68Analysis 03.03. Comparison 03 Multiple dose < 1 year: change in value, Outcome 03 Mid-upper arm circumference (cm)
68Analysis 03.04. Comparison 03 Multiple dose < 1 year: change in value, Outcome 04 Triceps skin fold (mm) . . .
69Analysis 03.05. Comparison 03 Multiple dose < 1 year: change in value, Outcome 05 Subscapular skin fold (mm) .
69Analysis 03.06. Comparison 03 Multiple dose < 1 year: change in value, Outcome 06 Haemoglobin (g/dL) . . . .
70Analysis 04.01. Comparison 04 Multiple dose < 1 year: end value, Outcome 01 Weight (kg) . . . . . . . . .
71Analysis 04.02. Comparison 04 Multiple dose < 1 year: end value, Outcome 02 Height (cm) . . . . . . . . .
72Analysis 04.03. Comparison 04 Multiple dose < 1 year: end value, Outcome 03 Mid-upper arm circumference (cm) .
72Analysis 04.04. Comparison 04 Multiple dose < 1 year: end value, Outcome 04 Triceps skin fold (mm) . . . . .
73Analysis 04.05. Comparison 04 Multiple dose < 1 year: end value, Outcome 05 Subscapular skin fold (mm) . . .
73Analysis 05.01. Comparison 05 Multiple dose > 1 year: change in value, Outcome 01 Weight (kg) . . . . . . .
74Analysis 05.02. Comparison 05 Multiple dose > 1 year: change in value, Outcome 02 Height (cm) . . . . . . .
74Analysis 06.01. Comparison 06 Multiple dose > 1 year: end value, Outcome 01 Weight (kg) . . . . . . . . .
75Analysis 06.02. Comparison 06 Multiple dose > 1 year: end value, Outcome 02 Height (cm) . . . . . . . . .
76Analysis 06.03. Comparison 06 Multiple dose > 1 year: end value, Outcome 03 Haemoglobin (g/dL) . . . . . .
76Analysis 07.01. Comparison 07 Analysis by worm prevalence or intensity, Outcome 01 Single dose: change in weight (kg)
77Analysis 07.02. Comparison 07 Analysis by worm prevalence or intensity, Outcome 02 Single dose: change in height
(cm) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
78Analysis 07.03. Comparison 07 Analysis by worm prevalence or intensity, Outcome 03 Multiple dose < 1 year: change in
weight (kg) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
79Analysis 07.04. Comparison 07 Analysis by worm prevalence or intensity, Outcome 04 Multiple dose < 1 year: change in
height (cm) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
80Analysis 07.05. Comparison 07 Analysis by worm prevalence or intensity, Outcome 05 Single dose: end value for weight
(kg) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
81Analysis 07.06. Comparison 07 Analysis by worm prevalence or intensity, Outcome 06 Single dose: end value for height
(cm) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
82Analysis 07.07. Comparison 07 Analysis by worm prevalence or intensity, Outcome 07 Multiple dose < 1 year: end value
for weight (kg) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
83Analysis 07.08. Comparison 07 Analysis by worm prevalence or intensity, Outcome 08 Multiple dose < 1 year: end value
for height (cm) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
84Analysis 08.01. Comparison 08 Subgroup and sensitivity analyses, Outcome 01 Single dose: change . . . . . .
86Analysis 08.02. Comparison 08 Subgroup and sensitivity analyses, Outcome 02 Single dose: end value . . . . .
89Analysis 08.03. Comparison 08 Subgroup and sensitivity analyses, Outcome 03 Multiple dose < 1 year: change in value
90Analysis 08.04. Comparison 08 Subgroup and sensitivity analyses, Outcome 04 Multiple dose < 1 year: end value .
91Analysis 08.05. Comparison 08 Subgroup and sensitivity analyses, Outcome 05 Multiple dose > 1 year: change in value
91Analysis 08.06. Comparison 08 Subgroup and sensitivity analyses, Outcome 06 Multiple dose > 1 year: end value .
iiDeworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Deworming drugs for treating soil-transmitted intestinal
worms in children: effects on growth and school performance
(Review)
Taylor-Robinson DC, Jones AP, Garner P
This record should be cited as:
Taylor-Robinson DC, Jones AP, Garner P. Deworming drugs for treating soil-transmitted intestinal worms in children: ef-
fects on growth and school performance. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD000371. DOI:
10.1002/14651858.CD000371.pub3.
This version first published online: 17 October 2007 in Issue 4, 2007.
Date of most recent substantive amendment: 13 August 2007
A B S T R A C T
Background
In areas where intestinal worm infections occur, the World Health Organization recommends treating all school children at regular
intervals with deworming drugs to improve growth and school performance. The evidence base for this policy needs to be established
for countries to commit resources to implement these programmes.
Objectives
To summarize the effects of deworming drugs used to treat soil-transmitted intestinal worms (nematode geohelminths) on growth and
school performance in children.
Search strategy
In May 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007, Issue
2), MEDLINE, EMBASE, LILACS, mRCT, and reference lists.
Selection criteria
Randomized and quasi-randomized controlled trials (RCTs) comparing deworming drugs for geohelminth worms with placebo or no
treatment in children aged 16 years or less, reporting on growth, nutritional status, school performance, or cognition tests.
Data collection and analysis
Two authors independently assessed the trials and evaluated methodological quality; one author extracted data, and another checked a
sample. Continuous data were analysed using the weighted mean difference (WMD) with 95% confidence intervals (CI). The random-
effects model (RE model) was used in the presence of statistically significant heterogeneity.
Main results
Thirty-four RCTs, including six cluster-RCTs, met the inclusion criteria. Four trials had adequate allocation concealment, and three
cluster-RCTs failed to take design effects into account in their analysis. Weight increased after one dose of a deworming drug (WMD
0.34 kg, 95% CI 0.05 to 0.64, RE model; 2448 children, 9 trials); however, there was considerable heterogeneity between trials that
was not explained by background intestinal worm infection or intensity. A meta-analysis of multiple dose trials reporting on outcomes
within a year of starting treatment showed no significant difference in weight gain (1714 children, 6 trials); however, one cluster-RCT
did show effects on weight at one year in a subgroup analysis. In the seven multiple dose trials with follow up beyond 12 months,
only one showed a significant increase in weight. Six of seven trials reported clear data on cognitive tests and school performance: five
reported no significant effects, and one showed some improvements in three out of 10 cognitive tests.
Authors’ conclusions
Deworming drugs used in targeted community programmes may be effective in relation to weight gain in some circumstances but not
in others. No effect on cognition or school performance has been demonstrated.
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P L A I N L A N G U A G E S U M M A R Y
Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
About a quarter of the world’s population is infected with one or more soil-transmitted worms. The main soil-transmitted worms
are roundworms, hookworms, and whipworms. Infections are widely distributed in tropical and subtropical areas, with most infected
people having more than one type of worm. The burden of disease falls disproportionately on the poor, where there is inadequate
sanitation, overcrowding, low levels of education, and lack of access to health care. These infections cause malnutrition and poor
growth for children, and some studies have suggested an association with poor performance at school. Improved sanitation and hygiene
are likely to be helpful. There are also three basic strategies for using drugs to treat these infections: (1) individual treatment based
on a diagnosis of infection (selective treatment); (2) groups at increased risk are treated (targeted treatment); and (3) treating whole
communities whether people have the infection or not (universal treatment). The targeted treatment is the one generally used. This
review of trials looked at targeted treatment with a range of deworming drugs for children, particularly focusing on growth and school
performance. Thirty-four trials were identified. These trials either looked at single or multiple doses, but only some assessed school
performance. After just one dose children’s weight improved, and more doses did not seem to improve this further. Only one of the
seven trials that assessed school performance found any positive effect, so it seems unlikely that there is a benefit here. Two trials looked
at adverse events, but the trials were small. Further research is needed.
B A C K G R O U N D
The World Bank rank soil-transmitted worms as number one in
terms of global burdenof disease in children agedbetween5 and14
years (World Bank 1993).More than a quarter of the world’s popu-
lation is estimated to be infectedwith one ormore of themost com-
mon soil-transmitted intestinal worms (nematode geohelminths)
(Chan 1997). These include roundworms (Ascaris lumbricoides),
hookworms (Necator americanus and Ancylostoma duodenale), and
whipworms (Trichuris trichura). Infections are widely distributed
in tropical and subtropical areas, andmost infected people harbour
multiple species (Montresor 2002; Cappello 2004). The burden
of disease falls disproportionately on the poor, where inadequate
sanitation, overcrowding, low levels of education, and lack of ac-
cess to health care make them particularly susceptible (de Silva
2003b).
The chronic effects of worm infestation are of most concern to
policymakers due to their potential effects on the developing child.
Hookworm and whipworm disease are associated with iron-defi-
ciency anaemia (Crompton 2000; de Silva 2003a). A fall in blood
haemoglobin levels has been associated with increasing intensity of
infection (Crompton 2003). Hookworm-induced iron-deficiency
anaemia has been associated with decreased physical activity and
worker productivity (Crompton 2003).
Worms are associated with malnutrition and growth impairment.
Roundworms obtain their nutrition from gastrointestinal con-
tents. The association with malnutrition is possibly mediated
through impaired fat digestion, reduced vitamin absorption (par-
ticularly vitamin A), and temporary lactose intolerance (WHO
2002). Whipworm infection has also been associated with malnu-
trition, although the precise mechanism for this is unclear (Cap-
pello 2004). Suggested mechanisms for the effects on growth in-
clude appetite suppression, increased nutrient loss, and decreased
nutrient absorption and utilization (Stephenson 2000; de Silva
2003a). Roundworm, hookworm, and whipworm disease have all
been associated with impaired physical growth in school children
(de Silva 2003a).
Observational studies have reported an association between worm
infection and lower scores on tests of school performance (Sakti
1999; Kvalsvig 2003). In a multiple-regression model based on
cross-sectional data, Sakti 1999 found that hookworm infection
was associated with worse scores in six out of 14 cognitive tests in
Indonesian school children. Severewhipworm (Trichurisdysentery
syndrome) was associated with low IQ, school achievement, and
cognitive function after a four-year follow up of a specific group
of Jamaican children with severe infection (Callender 1998).
While these associations would suggest potential benefit of de-
worming, poverty could confound the associations demonstrated.
Even with adjustment for known confounding factors, residual
confounding could be a problem. Hence randomized controlled
trials are important in determining whether these policies are ef-
fective.
Policies
Public health interventions to tackle worm infection are either
those that improve sanitation and hygiene or are concerned with
the administration of drug therapy to the whole population. These
have often been coupled with health education. The work of the
Rockefeller Sanitary Commission in the early 1900s led to the
recognition that sanitary reform was needed alongside chemother-
apeutic approaches to have an effect on worm prevalence (Horton
2003). In Japan, worms virtually disappeared over a 20-year pe-
riod after the Second World War; this has been credited to an in-
tegrated programme of sanitary reform combined with screening
and treatment of positive cases (Savioli 2002; Horton 2003). A
similar experience occurred in Korea (Savioli 2002). The impact
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of the chemotherapeutic element is difficult to assess. In countries
where an improvement in sanitation and hygiene has occurred as
a component of economic growth a parallel decline in the preva-
lence of geohelminths has occurred: for example, in Italy, between
1965 and 1980, the trichuriasis prevalence dropped from 65% to
less than 5% without control activity (Savioli 2002).
TheWorld Health Organization (WHO) policy in 2002 outlined
three categories of drug treatment (WHO 2002):
• Selective: individual deworming based on a diagnosis of infec-
tion.
• Targeted: group deworming where a (risk) group is treated with-
out prior diagnosis.
• Universal: population deworming in which the whole commu-
nity is treated irrespective of infection status.
Targeted treatment is promoted in preference to universal ap-
proaches. Individual screening is not recommended since the cost
is four to 10 times that of the treatment itself. The policy’s aim
appears to be to control morbidity by reducing the intensity of
infection in the most vulnerable populations. The strategy is to
target drug treatment at groups: pre-school-age children; school-
age children (between six and 15 years); and women of childbear-
ing age. The strategy requires a population survey for prevalence
and intensity of infection to determine the appropriate commu-
nity therapy. This ’community diagnosis’ determines the recom-
mended frequency of treatment (Table 01).
The policy promotes the use of schools, maternal and child health
clinics, and vaccination campaigns as a means to reach at-risk
groups. School-based programmes are advocated due to estab-
lished delivery channels and utilization of non-medical personnel,
with estimated costs varying from US$ 0.05 to 0.65 per child per
year for annual dosing (Savioli 2002; WHO 2002).
In areas with a high prevalence or intensity, the current policy rec-
ommends treatment two to three times per year. This is based on
modelling and reinfection prevalence studies: following drug treat-
ment worm populations tend to return rapidly to pretreatment
levels, in less than a year for roundworm and whipworm (Ander-
son 1991). Anderson 1991 suggests that to control morbidity in
areas of endemic infection, targeted treatment should be repeated
every three to four months for roundworm and whipworm, with
longer intervals acceptable for longer-lived species such as hook-
worm.
The WHO recommends monitoring both prevalence and inten-
sity. The control programme is intended to reduce the worm bur-
den in the 10% to 15% of children who are most heavily infected
in a particular population and to keep it low through repeated
treatments. The aim is to reduce morbidity and improve growth
and learning.
Recent policy trends
Current policies being promoted by the WHO (WHO 2002),
World Bank (World Bank 2003), and others depend on a belief
that mass treatment is effective. Indeed, recently some policymak-
ers advocate treating ’polyparasitism’ by treating the parasites that
cause ascariasis, trichuriasis, hookworm, lymphatic filariasis, on-
chocerciasis, schistosomiasis, and trachoma with ivermectin, al-
bendazole, azithromycin, and praziquantel. These four drugs are
donated by pharmaceutical companies, and the “overlapping speci-
ficity” would mean multiple pathogens would be targeted (Hotez
2006b). There is some conflating of the evidence around these in-
terventions. For example, the WHO states that deworming schis-
tosomes and soil-transmitted helminths helps (1) eradicate ex-
treme poverty and hunger; (2) achieve universal primary educa-
tion; (3) promote gender equality and empowerwomen; (4) reduce
child mortality and improve maternal health; and (5) compact
HIV/AIDS, malaria, and other diseases (WHO 2005). It would
seem that evaluating the effectiveness of these claims depends on
identifying that each ingredient has an effect on the outcomes
mentioned in the presence of a particular disease in a community.
This review examines the use of deworming drugs for soil-trans-
mitted helminths in relation to growth, nutrition, schooling, and
cognition.
Rationale for review
The previous version of this Cochrane Review found limited ev-
idence to support public health policies on deworming, with a
small but inconsistent effect onweight gain, and no data to support
an effect on cognitive function (Dickson 2000a). The uncertainty
raised by this review caused debate, with policy advocates ques-
tioning the review findings (Savioli 2000). Because deworming is
currently promoted as an effective and cheap way of improving
the health of children in poor countries, it is important to establish
the evidence base for this potentially powerful intervention. New
trials have been recently published, and other unpublished studies
have been made available to us. In this review update, we have
reapplied the inclusion criteria, repeated data extraction, added
new trials, and included additional analyses as recommended by
policy specialists. This Cochrane Review does not cover deworm-
ing and pregnancy, which is the subject of a separate Cochrane
Review (Haider 2005).
O B J E C T I V E S
To summarize the effects of deworming drugs used to treat soil-
transmitted intestinal worms (nematode geohelminths) on growth
and school performance in children.
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C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomized and quasi-randomized controlled trials (RCTs) that
were randomized by individual or cluster. We excluded cluster-
RCTs with only two units of allocation.
Types of participants
Children aged 16 years or less.
Types of intervention
Intervention
Deworming drugs for geohelminth worms, administered at any
location (eg health facilities, schools, and communities).
Deworming drugs for geohelminths in the WHO Model List of Essen-
tial Medicines (WHO 2006) are albendazole, levamisole, mebenda-
zole, pyrantel, and ivermectin. Others used are nitazoxanide, piper-
azine, tetrachlorethylene, and thiabendazole.
Control
Placebo or no treatment.
We included trials with concurrent treatment for schistosomiasis only if
both intervention and control arms received the same antischistosomal
regimen.
Types of outcome measures
Primary
• Growth: changes in weight and height.
• Nutritional status: weight, height, body mass index, mid-upper
arm circumference, and skin fold thickness.
• School performance: days absent, number of children dropping
out, examination performance.
Secondary
• Any test of cognition (eg tests of memory, concentration, lan-
guage development, and concept formation).
In trials that report on at least one of our primary or secondary
outcomes, we will also extract data, if available, on: (1) measures
of fitness or activity; (2) measures of appetite; (3) haemoglobin
values.
Adverse events
• Serious adverse events (death, life-threatening events, events
leading to hospitalization or significant impairment).
• Adverse events leading to discontinuation of treatment.
• Other adverse events.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Infectious Diseases Group methods used in
reviews.
The authors along with the Cochrane Infectious Diseases Group
Information Specialist have attempted to identify all relevant
trials regardless of language or publication status (published,
unpublished, in press, and in progress).
The Information Specialist searched the following databases
using the search terms and strategy described in Table 02:
Cochrane Infectious Diseases Group Specialized Register
(May 2007); Cochrane Central Register of Controlled Trials
(CENTRAL), published in The Cochrane Library (2007, Issue
2); MEDLINE (2000 to May 2007); EMBASE (2000 to May
2007); and LILACS (2000 to May 2007). The metaRegister of
Controlled Trials (mRCT) was also searched using ’helminth*
OR anthelminth*’(May 2007).
The authors also drew on existing reviews of the topic and
checked the citations of all the trials identified by the above
methods. We also re-appraised the studies identified in the
previous version of this review (Dickson 2000a).
M E T H O D S O F T H E R E V I E W
Trial selection
David Taylor-Robinson (DTR) checked the results of the search
for potentially relevant trials and retrieved full articles as required.
DTR and Paul Garner (PG) independently assessed the trial
eligibility using an eligibility form based on the inclusion criteria;
where there was uncertainty, all three authors participated in the
decision about inclusion. We checked that trials with multiple
publications were managed as one study.
Assessment of methodological quality
DTR and PG independently assessed the methodological quality
and presented the results in a table. Differences were resolved
by discussion. We classified generation of allocation sequence
and allocation concealment as adequate, inadequate, or unclear
(Juni 2001). Blinding was assessed as open (all parties aware
of treatment), participant or care provider/assessor blinded, or
participant and care provider blinded. We classified the inclusion
of all randomized participants (ie number evaluable/number
randomized) as adequate ifmore than 90%and inadequate if equal
or less than 90%. We used sensitivity analyses that excluded trials
with inadequate allocation concealment.
Data extraction
DTR extracted data using data extraction forms. PG extracted
and cross checked the data from a selection of papers. DTR
also requested PG to double-data extract particularly complicated
papers. Any differences were resolved by discussion. Where
4Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
methods, data, or analyses were unclear or missing, we contacted
authors for further details.
If there was discrepancy in the number randomized and the
numbers analysed, this was calculated and reported. In the
analysis, we used the number of participants reported on. For
individually randomized trials, the number of participants with
each outcome and the total number in each group were recorded
for dichotomous outcomes. For continuous outcome measures,
the aim was to record arithmetic means and standard deviations
for normally distributed data, and medians and ranges for non-
normally distributed data.
For trials randomized using clusters, we recorded the number
of clusters in the trial, the average size of clusters, and the unit
of randomization (eg household or institution). Where possible,
we documented the statistical methods used to analyse the trial
along with details describing whether these methods adjusted
for clustering or other covariates. When reported, estimates of
the intra-cluster correlation (ICC) coefficient for each outcome
were recorded. Where results had been adjusted for clustering, we
attempted to extract the point estimate and the 95% confidence
interval (CI).
Data analysis
We analysed data with Review Manager 4.2. We assessed
differences between the intervention and control groups using a
5% significance level.We stratified the analysis by dose (single and
multiple). The multiple dose trials are subdivided into those that
reported results within a year and after a year from the start of
treatment.We examined change from baseline in all outcomes and
then examined absolute values at the end of follow up. For trials
that did not provide data in this form we extracted medians and
ranges, and presented these in a table. For individually randomized
trials, we compared dichotomous data using relative risks (RR) and
compared continuous data using the weighted mean difference
(WMD). Cluster adjusted results were combined in the meta-
analysis using the generic inverse variance method. Non-adjusted
results were presented in tables.
Heterogeneity
To detect heterogeneity, we inspected forest plots and used the
chi-squared test with a 10% level of statistical significance. The
degree of heterogeneity was further quantified with reference
to the I2statistic (Higgins 2003). In the presence of significant
heterogeneity, we used the random-effects (RE) model for the
analyses and explored the following potential sources in subgroup
analyses: population prevalence and intensity of infection (as
per Table 01); nature of treatment programme (mass targeted
or selective based on screened individuals); age group (< five
years versus ≥ five years); drug type and manufacturer; treatment
setting (community, school, health post, hospital); and whether
children were malnourished or not. These were specified before
the analysis. In the event, we were able to examine in a subsidiary
analysis stratified by the community category in the population
being studied. We categorized the trials into three community
categories based on the level of geohelminth infection prevalence
or intensity in the study populations that we identified from
baseline prevalence and intensity data provided in the papers
(WHO 2002; Table 01). This is based on information on
both prevalence and intensity of infection. In the trials where
information on intensity was not provided, we estimated the
community category on the basis of quoted prevalence; it is
possible that the community category has been underestimated in
these trials.
We also carried out sensitivity analyses excluding trials where
children were screened for infection and excluding trials that were
inadequately concealed.
D E S C R I P T I O N O F S T U D I E S
Thirty-four trials reported in 43 articles met the inclusion criteria
(see ’Characteristics of included studies’); one was unpublished
and kindly supplied by the authors (Hall 2006). Eighteen were
excluded (see ’Characteristics of excluded studies’), and three are
ongoing (see ’Characteristics of ongoing studies’).
Location
The included trials were carried out in 20 different countries:
Kenya (4 trials); India (4 trials); Bangladesh (3 trials); Haiti,
Ethiopia, Indonesia, South Africa, Jamaica, and Zanzibar (2 tri-
als in each); Guatemala, Zaire, Benin, Cameroon, Sierra Leone,
Botswana, Malaysia, Uganda, Vietnam, Indonesia, and Tanzania
(1 trial in each).
Population
Children were recruited from school populations in 16 trials, com-
munities in 13 trials, and in health facilities or by health workers
in five trials. One of these recruited children on discharge from
hospital (Donnen 1998).
Eighteen trials were conducted in populations where worms were
of high prevalence or intensity (community category 1), eight in
populations with moderate prevalence and low intensity (category
2), and seven in populations with low prevalence and low inten-
sity (category 3). Classification was not possible in one trial (Freij
1979i).
Twenty-seven trials were based on mass targeted treatment of an
unscreened population. Seven trials studied children that were
screened and selected on the basis of their having high worm loads
(Freij 1979i; Freij 1979ii; Kvalsvig 1991i; Nokes 1992; Adams
1994; Simeon 1995; Sarkar 2002), and the purpose of three of
these trials was to measure cognitive outcomes (Kvalsvig 1991i;
Nokes 1992; Simeon 1995). Stephenson 1993 also studied an
infected subgroup of the larger unscreened study population for
cognitive outcomes.
Intervention and controls
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Twenty-six trials compared deworming drugs with a placebo or
no treatment:
• Albendazole: 19 trials; seven used a single-dose and 12 used
multiple doses (one trial used albendazole plus ivermectin in
one arm (Beach 1999)).
• Mebendazole: eight trials; three used a single dose and five used
multiple doses (two trials used mebendazole plus pyrantel in
trial arms (Rousham 1994; Lai 1995)).
• Pyrantel pamoate: five trials; two used a single dose and three
used multiple doses (one trial used pyrantel in a subgroup; two
trials used pyrantel plus mebendazole).
• Piperazine: three trials (single dose).
• Levamisole: one trial (multiple doses).
• Tetracholrethylene: one trial (single dose).
• Ivermectin: one trial (single dose; also used ivermectin plus
albendazole in one arm; Beach 1999).
In eight trials, both arms received vitamin or nutritional sup-
plementation, with the control arm receiving vitamins or nutri-
tional supplementation only (Awasthi 1995; Palupi 1997; Kruger
1996; Awasthi 2001; Dossa 2001; Sur 2005; Alderman 2006; Hall
2006).
Design
Six trials were cluster randomized (Table 03), and the other trials
used the individual as the unit of analysis.
Three out of the six cluster-RCTs analysed data using an appro-
priate method to take clustering into account. Stoltzfus 1997 ad-
justed for within-school correlations using the generalized estimat-
ing equations approach; and two trials used the cluster as the unit
of analysis and presented summary measures (mean values and
associated standard deviations) within a whole cluster (Awasthi
1995; Awasthi 2001; Table 03).
The three remaining cluster-RCTs did not take clustering into ac-
count. Rousham 1994 had 13 units of randomization (villages)
but analysed the data as if 1476 children were randomized. Al-
derman 2006 had 50 units of randomization (parishes) but anal-
ysed this as if 27,955 people had been individually randomized
for the main outcome (table 2 of their paper; Alderman, personal
communication). The unpublished trial, Hall 2006, which had
80 units of randomization (schools), analysed the 56,444 as if
they were individually randomized, although in this instance the
analysis did not demonstrate a significant figure (Hall, personal
communication).
Two trials had a factorial design. Kruger 1996 randomized indi-
vidual participants to albendazole or placebo, and, also, three of
the five schools in the trial received soup fortified with vitamins
and iron, and two received unfortified soup. Stoltzfus 2001 ran-
domized children to deworming drugs and daily iron; disaggre-
gated data for each treatment allocation group was not provided
for each outcome.
Follow-up periods for the trials that used a single dose ranged from
one to 11 months, while the follow-up periods for trials that used
multiple doses ranged from six months to 2.5 years.
Outcome measures
Growth and nutritional outcomes
These were measured in 33 trials (not measured in Nokes 1992).
Some trials reported absolute values or changes in absolute val-
ues of weight and height (or other anthropometric measures).
Many trials presented anthropometric data in terms of percentage
weight-for-age, weight-for-height, and height-for-age, and com-
pared the trial results to an external reference. Sometimes these
were converted into Z-scores. The external standard was usually
quoted as the National Centre for Health Statistics (NCHS) stan-
dard, but a variety of references were quoted (eg anthropometric
computer packages or country standards). These data have not
been used in the meta-analyses as the results are already incorpo-
rated in the values for weight and height.
Outcome data were incomplete in some trials and could not be
used inmeta-analysis. A number did not report summary outcome
data for each trial arm, and the results were reported in terms of
regression modelling outcomes or subgroup analyses. The results
of these trials are described in Table 04.
Appetite and activity
Five trials assessed appetite by measuring the amount of food con-
sumed for a snack or by a subjective report, and two trials assessed
activity levels.
School performance or cognitive outcomes
These were measured in seven trials, of which five used albenda-
zole and two used mebendazole. Five of these trials took place in
communities with high prevalence/intensity infections.
Adverse events
Two trials provided information on adverse events (Michaelsen
1985; Fox 2005). These were actively sought in Fox 2005.
M E T H O D O L O G I C A L Q U A L I T Y
See Table 05 for the methodological quality assessment and the ’Char-
acteristics of included studies’ for details of the methods used in each
trial.
For the 28 individually randomized trials, generation of allocation
sequence was adequate in six (Willett 1979; Simeon 1995; Beach
1999; Garg 2002; Fox 2005; Sur 2005), inadequate in four (Freij
1979i; Freij 1979ii; Lai 1995; Awasthi 2000), and unclear in the
other trials. The concealment of allocation was adequate in four
trials (Stoltzfus 2001;Garg 2002; Fox2005; Sur 2005), inadequate
in one (Awasthi 2000), and unclear in the other trials. For the six
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cluster-RCTs, generation of allocation sequence was adequate in
one (Alderman 2006) and unclear in five, and the method used to
conceal allocation was unclear in all six.
Two trials provided evidence that the participants, treatment
provider, and assessor were blinded (Beach 1999; Sur 2005). Two
trials did not use blinding (Awasthi 2001; Alderman 2006). De-
tails of blinding were unclear in seven trials. In the remaining tri-
als one or two of the participants, providers, and assessors were
blinded. Thirteen trials described the trial as being ’double blind’,
with incomplete information on who was blinded.
We calculated the percentage of randomized participants that were
evaluable. Overall, this ranged from 34% to 100%, with 12 trials
including 90% or more of the randomized participants (adequate)
cut-off. No data were available for one trial (Kvalsvig 1991i), and
data were unclear for two (Kloetzel 1982; Hall 2006). The per-
centage was particularly low in two of the trials measuring school
performance and cognitive outcomes: 73% in Nokes 1992; and
52% in Stoltzfus 2001.
R E S U L T S
The results are divided into three sections: (1) nutritional out-
comes after a single dose; (2) nutritional outcomes after multiple
doses (subdivided into within and after a year of treatment); and
(3) school performance and cognitive tests. The nutritional out-
come sections have three parts: analyses of change in nutritional
outcomes; analyses of end values of nutritional outcomes at com-
pletion of follow up; and narrative reports of potentially relevant
trials that could not be independently evaluated because they had
incomplete data sets (eg number of participants, variance, or val-
ues not provided meaning we were unable to analyse the data).
1. Nutritional outcomes after a single dose
Nine trials reported on change (four of these were early values from
multiple dose trials), 11 trials reported end values, and seven trials




Nine trials included data on mean weight change. No consistent
pattern was evident: some trials showed high values (over 700 g
for three trials), and others did not show a significant difference.
Themeta-analysis showed an overall gain of 0.34 kg (95%CI 0.05
to 0.64, RE model; 2448 children, 9 trials, Analysis 01.01), with
visible and statistical heterogeneity.
The exclusionof the two trials that did screen children for infection
(Adams 1994; Sarkar 2002) tipped the meta-analysis into non-
significance (2312 children, 7 trials, RE model, subgroup Anal-
ysis 08.01.01). In the subgroup analysis by community worm
prevalence and intensity (Table 01), six trials fell into high preva-
lence/intensity areas, one fell into a moderate prevalence/low in-
tensity area, and two into low prevalence/intensity areas (Analysis
07.01). This did little to explain the heterogeneity, with signifi-
cant heterogeneity in the five trials in the high prevalence/intensity
areas. A sensitivity analysis of trials with adequate or unclear al-
location of concealment meant that only one trial was excluded
(Awasthi 2000), making little difference to the estimate (Analy-
sis 08.01.02) There was only one trial that concealed allocation,
Garg 2002, and this did not reach statistical significance (Analysis
08.01.02).
Height
The single dose showed no statistically significant effect on change
in height from the baseline values in the meta-analysis (2449 chil-
dren, 9 trials, RE model, Analysis 01.02). Heterogeneity was sig-
nificant andwas not explained by community prevalence/intensity
(Analysis 07.02). A subgroup analysis of trials that did not screen
for infection made no difference to this finding (2313 children, 7
trials, Analysis 08.01.03). A sensitivity analysis of trials with ad-
equate or unclear allocation of concealment did not change this
finding (1462 children, 8 trials, Analysis 08.01.04).
Mid-upper arm circumference and skinfold tests
In a similar pattern to the weight gain results, three of the five
trials reported a significant effect and significant heterogeneity be-
tween the trials. Overall, there was no statistically significant dif-
ference in mid-upper arm circumference (5 trials, 823 children,
RE model, Analysis 01.03). The same three trials reporting signif-
icant effects on weight gain showed concurrent significant effects
with changes in triceps skinfold values (WMD 1.27 mm, 95%
CI 0.74 to 1.80, RE model; 394 participants, Analysis 01.04) and
subscapular skinfold (WMD 1.18 mm, 95% CI 0.90 to 1.46, RE
model; 394 participants, Analysis 01.05). Removing the one trial
that included screened children, Adams 1994, did not change the
conclusions for these three measures (RE model, subgroup Anal-
yses 08.01.05, .06, and .07).
Haemoglobin
Thehaemoglobin levels did not significantly change from the base-
line values after a single dose of mebendazole or albendazole in
the two trials that measured this (Garg 2002; Palupi 1997; 538
children, Analysis 01.06).
Appetite
Two trials reported an improvement in measures of appetite after
treatment (Adams 1994; Hadju 1996), but the outcome measures
were not comparable.
1.2. Values at end of follow up
Weight and height
A single dose had no statistically significant effect on weight (2980
children, 11 trials, Analysis 02.01) or height (2222 children, 8
trials, Analysis 02.02). These conclusions did not change when the
trials were grouped by community worm prevalence or intensity
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(Analyses 07.05 and .06), or when we removed trials that screened
children for infection (Freij 1979i; Adams 1994; Sarkar 2002;
Analyses 08.02.01 and .02) or one trial with inadequate allocation
concealment (Awasthi 2000; Analyses 08.02.03 and .04).
Mid-upper arm circumference and skinfold values
A single dose had no statistically significant effect on mid-upper
arm circumference (864 children, 7 trials, Analysis 02.03), tri-
ceps skinfold thickness (407 children, 4 trials, RE model, Analysis
02.04), or body mass index (407 children, 1 trial, Analysis 02.06).
The circumference and skinfold results did not alter when we re-
moved trials that screened children for infection (Freij 1979i; Freij
1979ii; Adams 1994; Analyses 08.02.05 and .06). However, there
was a statistically significant improvement in subscapular skinfold
thickness (WMD 0.73 mm, 95% CI 0.02 to 1.44, RE model; 394
children, 3 trials, Analysis 02.05). This result was no longer sig-
nificant once we removed Adams 1994, which included children
screened for infection (RE model, Analysis 08.02.07).
Haemoglobin
A single dose had no statistically significant effect on haemoglobin
levels (646 children, 4 trials, Analysis 02.07). Removing the one
trial that screened children for infection, Adams 1994, did not
alter this result (Analysis 08.02.08).
Fitness
A single dose significantly improved fitness, as measured by the
Harvard StepTest (WMD6.00, 95%CI 4.31 to 7.69; 86 children,
2 trials, Analysis 02.08).
Adverse events
Only two trials provided this information (Michaelsen 1985; Fox
2005). Fox 2005 found no serious adverse events (albendazole
0/46 versus placebo 0/43). Myalgia and cough were reported sig-
nificantly more frequently in the placebo group compared to al-
bendazole. Michaelsen 1985, which used tetrachlorethylene, re-
ported that 17% (19/119: results not given for separate trial arms)
of the children suffered adverse effects (nausea and ataxia) that
began one and a half hours after treatment. All symptoms dis-
appeared within four hours. This drug is not in current use as a
deworming drug.
1.3. Potentially relevant trials with incomplete data sets
We provide narrative summaries of the trial authors’ conclusions
from seven included trials that reported relevant but incomplete
data sets (Table 04), which we could not evaluate fully or use in
meta-analyses.
Beach 1999 did not detect a nutritional benefit of treatment after
four months for the entire study population (no figures provided).
Stratification by infection demonstrated small positive effects in
the treatment group for some anthropometric outcomes.
Fox 2005 did not provide results for the whole study population.
Results for height and weight were presented in the narrative for
subgroups infected with hookworm and Ascaris, and no signifi-
cant anthropometric changes were detected (no figures quoted).
In those infected with Trichuris, weight gain was greater in the
albendazole group.
Greenberg 1981 found no significant difference for all measured
anthropometric variables for the total group and for subgroups
defined by severity of infection (no figures provided).
Kloetzel 1982 reported the proportion of treatment or control
group that improved, deteriorated, or experienced no change. It
is unclear which anthropological measures were used in this cat-
egorization process. The proportions in each category were not
significantly different between trial arms.
Koroma 1996 found significant increases in weight-for-height,
weight-for-age, and height-for-age Z-scores recorded in rural and
urban treatment groups at six months.
Michaelsen 1985 found no significant difference in change in
mean for haemoglobin or weight for height at five months.
Nokes 1992 did not report on growth outcomes.
2. Nutritional outcomes after multiple doses
Eighteen trials investigated the effects of multiple doses of de-
worming drugs compared with placebo or no treatment, and seven
followed the children for more than one year. The dose interval
ranged from one to six months. The trials are divided into those
that reported outcomes within a year (11 trials) and outcomes at
one year or more (8 trials).
2.1. Outcomes within a year of starting treatment
Of the 11 trials that reported outcomes within a year (Willett
1979; Stephenson 1993; Simeon 1995; Kruger 1996; Watkins
1996; Hadju 1997; Stoltzfus 1997; Donnen 1998; Dossa 2001;
Stoltzfus 2001; Sur 2005), six trials reported on change, five trials




Multiple doses of deworming drugs had no statistically signifi-
cant effect on weight (1714 children, 6 trials, RE model, Analysis
03.01) or height (1715 children, 6 trials, Analysis 03.02). The
results did not alter significantly when we conducted a sensitivity
analysis and removed Awasthi 2000, the one trial with inadequate
allocation concealment (Analyses 08.03.01 and .02), or when we
analysed the trials in subgroups based on the estimated commu-
nity category (Table 01), which takes prevalence and intensity of
infection into account (Analyses 07.03 (RE model) and .04).
Mid-upper arm circumference and skinfold values
There was no statistically significant change in mid-upper arm
circumference (658 children, 4 trials, RE model, Analysis 03.03).
Two trials measured triceps skinfold thickness, with the mean
value decreasing with albendazole in one trial and increasing with
placebo in the other (254 participants, Analysis 03.04). The one
trial that measured subscapular thickness reported an increase in
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values (WMD 1.50 mm, 95% CI 1.23 to 1.77; 188 participants,
Analysis 03.05); this was the same trial that showed an increase
with triceps values.
Haemoglobin
No significant effect was demonstrated for the mean change in
haemoglobin (144 children, 2 trials, Analysis 03.06).
2.1.2. Values at end of follow up
No statistically significant effect was demonstrated for weight (5
trials, 2311 children, Analysis 04.01), height (4 trials, 1630 chil-
dren, Analysis 04.02), or mid-upper arm circumference (3 trials,
581 children, Analysis 04.03). Grouping trials by community cat-
egory (Table 01) or excluding trials with inadequate allocation
concealment did not alter the results for weight (Analyses 07.07
and 08.04.01) or height (Analyses 07.08 and 08.04.02). One trial
with 188 children showed significant improvement in mean tri-
ceps skinfold (WMD 1.90 mm, 95% CI 1.03 to 2.77; 188 par-
ticipants, Analyses 04.04) and subscapular thickness (WMD 1.70
mm, 95% CI 1.09 to 2.31; 188 participants, Analyses 04.05).
Dossa 2001 measured food intake in a sample from each trial arm,
but it did not present results that compared the groups.
2.1.3. Potentially relevant trials with incomplete data
Five trials included data that were relevant to this comparison but
provided insufficient data for us to independently evaluate the
statistical findings (no variance, no numbers of participants, or
values given were from regression analysis) (Table 04). Although
these trials meet the inclusion criteria, we could not evaluate the
data fully or use them in meta-analyses, and have summarized the
trial authors’ conclusions below.
Hadju 1997 found no significant differences in change in weight-
for-age, height-for-age, weight-for-height, or mid-arm circumfer-
ence Z-scores detected between treatment groups on basis of mul-
tivariate analyses.
Simeon 1995 found no significant differences between treatment
groups in height-for-age Z-score or body mass index.
Stoltzfus 1997 was a cluster-RCT in three districts with three arms
(placebo, mebendazole twice a year, mebendazole three times a
year) with four schools in each arm. Weight and height change
were then evaluated at one year, using multiple linear regression to
adjust for characteristics that differed at baseline. In a subgroup of
under 10 year olds, the twice-yearly treated group experienced sig-
nificantly greater weight gain (kg) compared to the control group.
In the thrice-yearly treatment group the difference was not sig-
nificant. The thrice-yearly treated group also experienced signif-
icantly greater height gain (cm) compared to control, but in the
twice-yearly treatment group the difference was not significant.
There were no significant differences found in the subgroup of
children aged over 10 years. Deworming had no significant effect
on haemoglobin change in an adjusted analysis presented for the
whole study group.
Stoltzfus 2001 found that treatment significantly reduced the
prevalence of mild wasting malnutrition in a subgroup of children
aged less than 30 months. Treatment is reported as significantly
reducing the prevalence of poor appetite across the whole group.
Willett 1979 found no statistical difference in growth rates in
terms of height and weight between the two groups.
2.2. Outcomes one year or more after starting treatment
Of the seven multiple dose trials that reported outcomes at one
year or more (Rousham 1994; Awasthi 1995; Lai 1995; Awasthi
2000; Awasthi 2001; Alderman 2006; Hall 2006), three reported
on change, two reported on end values, and four included data that
were relevant to this comparison but could not be independently
evaluated.
2.2.1. Change
Of the three trials, one randomized individuals (Awasthi 2000)
and two randomized clusters (Awasthi 1995; Awasthi 2001).
Weight and height
For weight, two trials did not demonstrate a difference or a trend
towards a difference, whereas one trial showed a marked increase
in weight with albendazole (1219 participants, RE model, Anal-
ysis 05.01). The meta-analysis is in the direction of benefit with
albendazole, but this is not significant, and the heterogeneity is
evident visually and statistically. None of the three trials showed
an effect on height (1219 participants, Analysis 05.02). Sensitivity
analyses, which excluded the one trial with inadequate allocation
concealment (Awasthi 2000), showed again that the point esti-
mate was consistent with benefit for albendazole, but this was not
significant (Analysis 08.05).
2.2.2. Values at end of follow up
Weight and height
Two trials reported end values for weight (RE model, Analysis
06.01) and height (Analysis 06.02). One of these trials, Awasthi
2001, showed a difference of borderline significance in favour of
albendazole (Analysis 06.01); however, this trial had not shown
a difference in weight gain (RE model, Analysis 05.01). Removal
of Awasthi 2000 left only one trial in the analysis (Awasthi 2001,
Analysis 08.06).
Mid-upper arm circumference and skinfold values
Rousham 1994 reported no significant improvement in Z-scores
for mid-upper arm circumference after treatment with mebenda-
zole (Table 06).
Haemoglobin
No significant effect was demonstrated onmean haemoglobin lev-
els (1045 children, 1 trial, Analysis 06.03).
2.2.3. Potentially relevant studies with incomplete data sets
Four trials included data that were relevant to this comparison but
were insufficient for us to independently evaluate the statistical
findings (no variance, no numbers of participants, no adjustment
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for cluster randomization, or values given were from regression
analysis). Although these trialsmet the inclusion criteria, these data
are more difficult to evaluate and cannot be used in meta-analyses.
Instead we have summarized the trial authors’ conclusions (see
Table 04).
Lai 1995 found no difference in height or weight between the
treatment and control groups at the end of the two-year follow
up.
Alderman 2006 reported on weight gain by 27,995 children living
in 48 parishes randomized by coin flip to either albendazole or
nothing. There was a weight gain of 2.413 kg in the treatment
parishes and 2.474 kg in the control parishes at an unspecified
follow-up point. Although the 154 g difference was reported as
statistically significant in the paper, the trial authors assumed that
the children were individually randomized. We contacted the trial
authors who confirmed this result was unadjusted; the authors
have since submitted a correction to the journal, which shows
no significant difference is detected in the difference for weight
gain between intervention and control groups (difference 154 g;
95% CI -19.7 to 330 g). Alderman’s analysis in the paper also
provides regression models looking at weight gain as a function
of whether children attended child health days (which ignores
randomization). These are corrected for cluster sampling but are
not a randomized comparison.
Hall 2006 reported on 80 schools in Vietnam that were random-
ized to receive albendazole or vitamin A. The authors reported on
weight and height gain in children in the intervention and control
groups after two years. No significant effect was demonstrated.
The analysis assumed individual randomization. A regression anal-
ysis controlling for age, sex, socioeconomic status, and days absent
from school showed no statistically significant effect on weight,
height, or educational tests.
Rousham 1994 randomized 13 villages in which the children re-
ceived mebendazole, pyrantel, or placebo, and were measured for
height andweight. The paper only presentsANOVAs for change in
Z-scores for height-for-age, weight-for-age, andweight-for-height,
with a follow-up period of about 18 months. No significant im-
provement in the treatment group was detected.
3. School performance and cognitive tests
The results of the seven trials reporting school performance or
learning outcomes are summarized in Table 06. The trials used
either albendazole (five trials: one single dose and four multiple
dose) or mebendazole (two trials: one single dose and one multiple
dose). They examined a variety of outcome measures, including
measures of school performance (school attendance and dropout
rates) in two trials, development status in two trials, and measured
tests of cognition in four trials. Overall, five of the trials demon-
strated no treatment effect (Simeon 1995; Watkins 1996; Awasthi
2000; Stoltzfus 2001; Hall 2006), one trial noted an improvement
in three out of 10 cognitive tests used (Nokes 1992), and one trial
did not report the results clearly (Kvalsvig 1991i).
D I S C U S S I O N
Trial quality
Only three recent trials provided information to assure good
methodological quality in terms of allocation sequence and con-
cealment, blinding, and inclusion of randomized participants in
the analysis (Garg 2002; Fox 2005; Sur 2005). Only one other trial
used an adequate method to conceal allocation (Stoltzfus 2001).
About two-thirds of the trials (22/34) did not include over 90%
of the randomized participants in the analysis. This was low in
some trials, including trials conducted recently (eg 52% in Stoltz-
fus 2001).
Of the six cluster-RCTs, only three took adequate account of clus-
ter randomization (Awasthi 1995; Awasthi 2001; Stoltzfus 1997).
This has a substantive impact on the interpretation of the trials.
For example, the significant difference between intervention and
control quoted on the cover of the BMJ for Alderman 2006 as-
sumed 27,995 children had been individually randomized. When
we clarified this with the authors, they provided the BMJ with a
correction, which showed that no significant difference was de-
tected in weight gain between intervention and control groups;
this correction has not yet been included in the BMJ (checked in
July 2007).
We excluded one large study,Miguel 2004, an economic analysis of
a studywhere some of the comparisons could potentially have been
quasi-randomized cluster comparisons. It included75 schoolswith
a total of 30,000 pupils enrolled. The interventionwas phased over
time, and there were two comparisons, one in 1998 and one in
1999 if the analysis is comparative within each individual year. All
clusters in the treatment group were assigned albendazole on the
basis of a prevalence over 50%.The trial assigned schools to receive
praziquantel with schistosomiasis prevalence over 30%. On this
basis six of 25 treatment schools met the cut off in 1998, and 16
met the cut-off in 1999. The albendazole/praziquantel treatment
was phased over several years, and thus the control group and
intervention group changed in size over the course of the trial.
In 1998, there were 25 intervention schools (group 1) and 25
control schools (groups 2). In 1999, there were 50 intervention
schools (groups 1 and 2) and 25 control schools (group 3). The
results for the 1998 comparison were presented. It may be possible
to obtain some information in meta-analysis by excluding those
schools that were given praziquantel, but this is problematic as it
will lead to large, post-randomization exclusions. As it happens, the
study did not detect a significant difference at the 95% confidence
level in the treatment group for the height-for-age Z-score (0.09,
SE 0.05, P > 0.05), weight-for-age Z-score (-0.00, SE 0.04), or
haemoglobin concentration (1.6 g/L, SE 1.4). Data were given
on school participation by subgroup, and some showed benefit
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in schools allocated albendazole, but it is not clear whether the
significance testing took clustering into account.
Growth and nutritional status outcomes
The included trials reported a range of growth and nutritional
status outcomes. We used numerical values for change and for
absolute values, but did not use growth data expressed as a per-
centage of standards. As these data were derived from the abso-
lute values, we used these values for evidence of benefit. We knew
the nutritional data would be captured in the absolute values and
wanted to reduce selective reporting through collection of multi-
ple variables from papers that are all derived from the same ba-
sic outcomes measured in the trial. We noted that in some trials
there was a discrepancy between what was measured and what was
reported; for example, Nokes 1992 recorded but did not report
anthropometric data. This is a concern as it may indicate selective
reporting. However, given the relatively poor quality of methods
in these papers, we did not systematically analyse this.
The review showed a significant difference in weight change after
a single dose of a deworming drug. There was significant hetero-
geneity and a relatively small number of trials in this analysis, so it
is unclear whether this reflects a difference in the size of an effect
or that the intervention is effective in some circumstances but not
in others. However, the potential size of the effect is quantitatively
important, with increases of 0.34 kg during the follow-up period
of one to 11 months (range).
The results for multiple dose trials with less than a year’s follow up
that were evaluable bymeta-analysis did not demonstrate an effect.
Five other trials provided data that could not be fully evaluated.
Three of these showed no significant effect. Two trials, one of
which one was cluster randomized, demonstrated improvements
in growth outcomes in subgroup analyses (Stoltzfus 1997; Stoltzfus
2001).
For follow up of more than a year, the results for multiple dose
trials evaluable in meta-analysis did not demonstrate statistically
significant effects on weight or height. For weight change there
was heterogeneity in the analysis, with one cluster-RCT showing
benefit: interpretation is not easy, but the data tend to suggest that
the intervention may be effective in some circumstances and not
in others. Four other trials provided data that could not be fully
evaluated. Three trials did not show an effect; one was a large,
unpublished cluster-RCT from Vietnam. The fourth trial was a
cluster-RCT published in the BMJ where it reported a significant
effect, but this subsequently found to be due to incorrect analysis
(Alderman 2006).
Our review included trials reporting on growth, nutritional status,
school performance, and cognition measures. It does not compre-
hensively assess the effects of deworming drugs on haemoglobin
values. Gulani and colleagues did this recently and reported a mar-
ginal increase in mean values that could translate into small reduc-
tion (they estimate 5% to 10%) in anaemia in a population with
a high prevalence of intestinal helminths (Gulani 2007).
The previous version of this review, Dickson 2000a, generated
feedback from authors who stated that the impact of treatment
must be considered in the context of intensity of infection (Cooper
2000; Savioli 2000). In response, we stratified the trials in terms
of estimated community category using WHO methods (Table
01). This reflects the level of the worm infection prevalence or
intensity in the study populations. We found that a single dose
of a deworming drug has a significant effect on the mean change
in weight in the children with an initial high worm prevalence or
intensity compared with no effect in the group with low worm
prevalence or intensity. This is in line with WHO policy (WHO
2002), which is based on the premise that these groups are likely
to benefitmost from treatment (Anderson 1991; Montresor 2002;
WHO 2005).
Other people responded to the Dickson 2000a version of this
Cochrane Review by suggesting that studies of short-term treat-
ment cannot assess the long-term benefits of regular treatment
(Bundy 2000). In this update, however, observed short-term im-
provements in weight gain were generally not reproduced in the
multiple dose trials with longer follow up. This is difficult to ex-
plain. It has been suggested that resistance to deworming drugs
may be a factor that limits the effectiveness of periodic deworming
(Hotez 2006b). Some people have also questioned whether alben-
dazole itself can adversely affect growth (Hotez 2006b).
Some policymakers state that our analysis is irrelevant as the pur-
pose of giving deworming drugs to all school children is to benefit
a small subgroup with heavy worm infections; they argue that in
these circumstances, demonstrating a population effect is irrele-
vant. Our response to this is that trialists power their studies to
detect these differences in these subgroups and then analyse their
results by worm burden to evaluate whether their hypothesis is
correct. In this systematic review, the stratified analysis by trials
in relation to endemicity of worms suggests an effect in high en-
demicity areas for a single dose, but not for multiple doses.
Schistosomiasis and filariasis are helminth infections that also
cause disease. In practice, individuals and communities are often
infected with more than one helminth infection, and there are
now international policy moves to integrate control of these infec-
tions by mass administration of several deworming drugs at once
(Molyneux 2005). However, there is a need to demonstrate that
a drug is effective on a particular parasite and its effects on hu-
mans before conflating all the drugs into a basket treatment for all
helminth infections, and assuming they are all effective.
School performance and cognitive outcomes
Only three trials investigated measures of school performance
(Simeon 1995;Watkins 1996; Hall 2006). All three of these found
that the deworming drugs made no statistical difference compared
with the control intervention. All of the trials that reported cog-
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nitive outcomes, with the exception of Nokes 1992, also failed to
demonstrate any effect. The trials used a range of cognitive tests,
which seems to reflect the difficulty inherent in choosing appro-
priate cognitive performance tests since there is no accepted test
battery that can be applied across cultures and settings and, as
Miguel 2004 points out, the mechanisms for any putative effects
are unknown. Three of the trials studied children selected on the
basis of high worm loads (Kvalsvig 1991i; Nokes 1992; Simeon
1995). Simeon 1995 has suggested that treatment may be more
beneficial in heavily infected children.
Summary
• A meta-analysis of trials showed that children gained more
weight with a single dose of a deworming drug compared to
those who did not receive a deworming drug. However, there
was variation between trials, with some demonstrating substan-
tial effects and others not detecting a difference. Background
helminth infection prevalence and intensity did not explain the
differences between trials.
• In trials evaluating multiple doses, 11 trials measured outcomes
within a year. In a meta-analysis of six trials examining weight
and height change, no significant difference was detected. In
one cluster-RCT, significant results were found in subgroups
for weight and height, in favour of the intervention.
• In trials evaluating multiple doses, seven trials had outcomes
at one year or more. One cluster-RCT showed a statistically
significant effect on weight gain, but other trials did not show
such effects, including two recent large cluster-RCTs.
• No clear effect has been demonstrated on school performance
or cognitive function.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• Deworming drugs used in targeted community programmes
may be effective in relation toweight gain in some circumstances
but not in others. Also, there is no direct evidence from trials
to show that this depends on background helminth prevalence
or intensity. Whether it has an effect on school performance or
cognition is unknown.
• We suggest that policy advocates make clear the research ev-
idence has sometimes demonstrated benefits and sometimes
has not demonstrated benefit. Guideline developers and policy
makers at global, national, and local levels should be allowed to
consider carefully the evidence carefully before committing to
investing existing resources in delivering these programmes.
Implications for research
• This is a potentially important intervention. The large cluster-
RCT in progress in Lucknow, India (Lucknow ongoing) may
help in identifying whether this intervention is worthwhile.
• Further research is required to determine the factors that will
allow policymakers to predict whether it is worthwhile to im-
plement the intervention in a community.
• Further research is required before policymakers can be clear
whether the intervention is of benefit or not on children’s long-
term growth and school performance.
• Trial authors are encouraged to present trial data in line with
CONSORT guidelines (Moher 2001).
• Authors of cluster-RCTs should report their data adjusting for
design effects. We recommend trials that use current standards
of design and are planned together to allow an individual patient
data meta-analysis to correct for clustering and to help explore
subgroup effects.
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T A B L E S
Characteristics of included studies
Study Adams 1994
Methods Randomized controlled trial
Generation of allocation sequence: paired by worm burden
Allocation concealment: unclear
Blinding: participants only; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 98% (55/56)
Length of follow up: 2.25 months (9 weeks)
Participants Number analysed for primary outcome: 55
Inclusion criteria: children in nursery and standard 1 classes of Mvindeni Primary School in Kwale, Kenya;
> 500 eggs/g hookworm or > 1000 eggs/g Trichuris or Ascaris; pre-pubertal; > 5 years old
Exclusion criteria: severe anaemia (haemoglobin < 75 g/L)
Interventions Single dose versus placebo
1. Albendazole: 3 x 400 mg doses on 3 consecutive days
2. Identical placebo
Treatment strategy: screened children then randomized and treated infected children
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Characteristics of included studies (Continued )
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
7. Mean triceps skinfold thickness
8. Mean change in triceps skinfold thickness
9. Mean subscapular skinfold thickness
10. Mean change in subscapular skinfold thickness
11. Mean haemoglobin post-treatment
12. Activity levels (a measure of gross motor activity of legs)
13. Self rating of appetite
Not included in review: helminth prevalence and intensity (arithmetic and geometric mean eggs/g); baseline
and post-intervention values for arm muscle area and arm fat area; Z-scores for weight, height, weight-for-
height, mid-upper-arm circumference, triceps skinfold, subscapular, arm muscle, and arm fat area
Notes Location: Kenya
Community category: 1
Allocation concealment B – Unclear
Study Alderman 2006
Methods Cluster-randomized controlled trial
Generation of allocation sequence: coin toss
Allocation concealment: unclear
Blinding: none
Inclusion of all randomized participants (number evaluable/number randomized): 75% 27,995/37,165
Length of follow up: 3 years
Participants Number analysed for primary outcome: 27,995 in 48 clusters
Age range: 1 to 7 years
Inclusion criteria: children aged 1 to 7 in 50 parishes in Uganda selected by the government on the basis that
around 60% of children aged 5 to 10 years in these parishes were infected with intestinal nematodes
Exclusion criteria: sick children
Interventions Multiple dose versus no treatment
1. Albendazole: 400mg tablet (Zentel,GSK) every 6months, although in the event a year elapsed between the
first and second treatment round; given in conjunction with a child health package including vaccinations,
vitamin A, and health promotion
2. Child health package including vaccinations, vitamin A, and health promotion
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
Notes Location: Uganda
Community category: 2
Weight gain does not take into account the effects of cluster randomization (correspondence with author)
Allocation concealment B – Unclear
Study Awasthi 1995
Methods Cluster-randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
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Characteristics of included studies (Continued )
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): 87% (3514/3999)
Length of follow up: 2.5 years
Participants Number analysed for primary outcome: 3514
Age range: 1 to 4 years
Inclusion criteria: children aged 1 to 4 from 50 randomly selected urban slums in Lucknow
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole plus placebo: 400 mg albendazole plus 2 mL vitamin A every 6 months
2. Placebo: 2 mL vitamin A every 6 months
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment




Means of cluster means used in analysis; details of correspondence from previous review suggest that trial
ongoing; data for 3-year follow up are provided from R Dickson’s correspondence with the author for the
Dickson 2000 Cochrane Review, but the loss to follow up is very high: only 24% analysed
Allocation concealment B – Unclear
Study Awasthi 2000
Methods Quasi-randomized controlled trial
Generation of allocation sequence: 32 clusters randomly selected, and then children allocated to a serial
number; those with odd or non-zero ending numbers were assigned to placebo
Allocation concealment: not concealed
Blinding: participants only; provider not blinded; assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 98% (1045/1061)
Follow up: 2 years
Participants Number analysed for primary outcome: 1045
Age range: 1.5 to 3.5 years
Inclusion criteria: children living in 32 randomly selected urban slums; registered with an Anganwadi worker
(health worker); between 1.5 to 3.5 years of age
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole powder: 600 mg every 6 months for 2 years
2. Placebo: calcium powder
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Developmental status (Denver Questionnaire): reported as proportion with normal development
Not included in review: prevalence of underweight and stunting over 2 years as defined by Z-scores,
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Characteristics of included studies (Continued )
Allocation concealment C – Inadequate
Study Awasthi 2001
Methods Cluster-randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: none
Inclusion of all randomized participants (number evaluable/number randomized): 83% (1672/2010)
Length of follow up: 1.5 years
Participants Number analysed for primary outcome: 124 slums randomized containing 1672 children
Inclusion criteria: clusters selected if they have functional community workers in slum areas of Lucknow;
within each cluster, children recruited if aged between 0.5 and 1 year, on basis of survey register held by each
worker of their particular area
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole plus placebo: albendazole suspension (concentration not stated) (Zentel, SZB) every 6months
and 100,000 units of vitamin A every 6 months
2. Placebo: 100,000 units of vitamin A every 6 months
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment (not used due to question over quoted standard error)
Not included in review: stool smear for Ascaris prevalence on a subsample of the group; death rates
Notes Location: India
Community category: 3
Means of cluster means used in analysis. The results (weight gain) in the abstract differ from the text
Allocation concealment B – Unclear
Study Beach 1999
Methods Randomized controlled trial
Generation of allocation sequence: random-numbers table
Allocation concealment: unclear
Blinding: participants, provider, and assessors
Inclusion of all randomized participants (number evaluable/number randomized): 88.4% (853/965)
Length of follow up: 4 months
Participants Number analysed for primary outcome: 853
Inclusion criteria: all children attending 5 schools (grades 1 to 4)
Exclusion criteria: haematocrit < 22%
Interventions Single dose versus placebo
1. Albendazole: 400 mg (SmithKlineBeecham, Philadelphia or generic BeltaPharm, Milan)
2. Ivermectin: 200 to 400 µg/kg (mean 282.7 µg/kg) (Merck, West Point, PA)
3. Albendazole plus ivermectin
4. Placebo: 250 mg vitamin C
Treatment strategy: randomized and treated all children
Outcomes 1. Height
2. Weight
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Characteristics of included studies (Continued )




Results presented in a stratified analysis as per individual infection: disaggregated results not presented;
measures of error not given in tables
Allocation concealment B – Unclear
Study Donnen 1998
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): 86% (311/358)
Length of follow up: 1 year
Participants Number analysed for primary outcome: 222
Inclusion criteria: children aged 0 to 72 months eligible on discharge from hospital where primary cause for
admission is malnutrition
Exclusion criteria: none stated
Interventions Multiple doses versus placebo and no treatment
1. Mebendazole: 500 mg at start and every 3 months
2. Placebo: 60 mg vitamin A at start and 3 months
3. No treatment
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
Not included in review: vitamin A levels; Z-scores for height-for-age, weight-for-age, weight-for-height
(NCHS reference); egg counts (eggs/g: Kato Katz method)
Notes Location: Zaire
Community category: 1
Unadjusted data not provided in original paper; results of multiple-regression models presented on basis of
stratifications into vitamin A status and sex; results in meta-analysis from R Dickson’s correspondence with
author when preparing the Dickson 2000 Cochrane Review
Allocation concealment B – Unclear
Study Dossa 2001
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear for participants, provider, and assessor, but described as “double-blind”
Inclusion of all randomized participants (number evaluable/number randomized): 79% (140/177)
Length of follow up: 10 months
Participants Number analysed for primary outcome: 65
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Characteristics of included studies (Continued )
Inclusion criteria: children aged 3 to 5 years; not acutely unwell
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Albendazole plus iron: 200 mg albendazole per day for 3 consecutive days repeated 1 month later plus
iron placebo
2. Placebo: iron
3. Albendazole: 200 mg per day for 3 consecutive days repeated 1 month later plus iron placebo
4. Placebo plus placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
3. Mean change in mid-upper arm circumference
4. Mean change in triceps skinfold thickness
5. Mean haemoglobin post-treatment
Not included in review: weight-for-height Z-score and height-for-age Z-score at 3 and 10 months (both after
2 doses)
Not included in review
Measured but not reported: Z-scores for weight-for-height, height for age using NCHS reference data; egg
count (arithmetic and geometric mean); prevalence, intensity; food intake over 3 days in subset at end of
trial (not at baseline)
Notes Location: Benin
Community category: 2
Allocation concealment B – Unclear
Study Fox 2005
Methods Randomized controlled trial
Generation of allocation sequence: random-number table
Allocation concealment: centrally coded allocation system broken after baseline measures taken
Blinding: described as double blind; provider unclear
Inclusion of all randomized participants (number evaluable/number randomized): 97% (626/646)
Length of follow up: 6 months
Participants Number analysed for primary outcome: 626
Inclusion criteria: children aged 5 to 11 years attending any of 12 primary schools in Haiti where no other
deworming activity was taking place
Exclusion criteria: none stated
Interventions Single dose versus placebo:
1. Albendazole 400 mg
2. Placebo (250 mg vitamin C tablet)
3. Albendazole 400 mg plus single dose of 6 mg/kg diethylcarbamazine (DEC)
4. Placebo plus placebo (2 x 250 mg vitamin C tablets)
Treatment strategy: randomized and treated all children
Outcomes 1. Weight: final and change in weight
2. Height: final and change in height
3. Adverse effects
Not included in review: worm intensity and prevalence; microfilarial density
Notes Location: Haiti
Community category: 2
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Characteristics of included studies (Continued )
Weight and height outcomes are only presented for a subgroup of children infected with Trichuris
Allocation concealment A – Adequate
Study Freij 1979i
Methods Quasi-randomized controlled trial: boys matched into pairs of equal age and nutritional status
Generation of allocation sequence: not described
Allocation concealment: unclear
Blinding: described as double blind
Inclusion of all randomized participants (number evaluable/number randomized): 100% (13/13)
Length of follow up: 28 days
Participants Number analysed for primary outcome: 13
Inclusion criteria: boys attending mother and child clinic with Ascaris on stool smear; aged 1.5 to 5 years
with no history of diarrhoea for preceding 2 weeks; no fever; no respiratory symptoms; no signs of severe
disease
Exclusion criteria: children diagnosed with other parasites; excluded girls to eliminate the contamination of
samples with urine
Interventions Single dose versus placebo
1. Piperazine: 3 g single dose
2. Placebo syrup: single dose
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Weight
2. Mid-upper arm circumference
3. Triceps skinfold thickness
Not included in review: Ascaris worm count
Notes Location: Ethiopia
Community category: unclear
The authors mention that boys were matched in pairs so that if there were drop outs they could be replaced.
They do not indicate if there were any drop outs. Standard deviations calculated from individual data
Freij 1979i and Freij 1979ii were reported in the same article
Allocation concealment B – Unclear
Study Freij 1979ii
Methods Quasi-randomized controlled trial: children divided into groups similar for age and nutritional status
Generation of allocation sequence: not described
Allocation concealment: unclear
Blinding: described as double blind
Inclusion of all randomized participants (number evaluable/number randomized): 100% (44/44)
Length of follow up: 34 days
Participants Number analysed for primary outcome: 44
Inclusion criteria: 92 children 1 to 5 years from a community morbidity study
Interventions Single dose versus placebo
1. Piperazine: 3 g/day for 2 days
2. Placebo: for 2 days
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Mid-upper arm circumference
2. Morbidity
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Characteristics of included studies (Continued )
Not included in review: weight in % of Harvard standard; authors had intended to measure bicep and tricep
skinfolds, but staff were unable to take these measurements
Notes Location: Ethiopia
Community category: 3
Freij 1979i and Freij 1979ii were reported in the same article
Allocation concealment B – Unclear
Study Garg 2002
Methods Randomized controlled trial
Generation of allocation sequence: computer-generated list of random numbers
Allocation concealment: drugs kept in envelope until after baseline assessment
Blinding: assessor; participants unclear; provider not blinded
Inclusion of all randomized participants (number evaluable/number randomized): 93% (347/370)
Length of follow up: 6 months
Participants Number analysed for primary outcome: 347
Inclusion criteria: sick children 2 to 4 years old presenting to 3 government health centres in Bungamo
district, without palmar pallor
Exclusion criteria: children with palmar pallor
Interventions Single dose versus placebo
1. Mebendazole: 500 mg (Vermox, Janssen, Belgium)
2. Placebo: sucrose starch capsule
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean haemoglobin post-treatment
6. Mean change in haemoglobin post-treatment
Not included in review:Z-scores forweight-for-age, height-for-age, andweight-for-height; egg count (formol-
ethyl acetate concentration method) in categories of intensity
Notes Location: Kenya
Community category: 3
Allocation concealment A – Adequate
Study Greenberg 1981
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: participants; described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 82% (152/185)
Length of follow up: 11 months
Participants Number analysed for primary outcome: 152 aged 1.5 to 8 years
Inclusion criteria: children aged 1.5 to 8 years living in Nandipara, Bangladesh; 50% entered into study;
only those who provided stool sample and had anthropometric measurements taken at first visit entered
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Piperazine citrate: 80 mg/kg added to flavoured syrup; 2 doses in 2-week period
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Characteristics of included studies (Continued )
2. Placebo: syrup only
Treatment strategy: randomized and treated all children
Outcomes 1. Cure rates
2. Reinfection rates
3. Weight-for-height
4. Height-for-age (NCHS reference)
5. Weight-for-age (graphically)
6. Other measured parameters not reported: weight; height; triceps skinfold thickness; mid-upper arm cir-
cumference; chest circumference; abdominal girth; egg counts (Dunn’s method); prevalence; triceps skinfold
for age; mid-upper arm circumference for age (Tanner reference charts)
Notes Location: Bangladesh
Community category: 1
Groups stratified by intensity of Ascaris infection
Allocation concealment B – Unclear
Study Hadju 1996
Methods Randomized controlled trial
Generation of allocation sequence: “by descending A. lubricoides egg count”
Allocation concealment: unclear
Blinding: participants; described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 85% (64/75)
Length of follow up: 1.75 months (7 weeks)
Participants Number analysed for primary outcome: 64
Inclusion criteria: boys aged 6 to 10 years attending second grade at 3 primary schools; completed assessment
and provided a stool sample; randomized by descending hookworm count (all treated)
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Pyrantel palmoate: 10 mg/kg
2. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Appetite: consumption test (mL porridge) and self assessment




Large drops in geometric mean egg counts in placebo noted
Allocation concealment B – Unclear
Study Hadju 1997
Methods Randomized controlled trial
Generation of allocation sequence: “by sex and egg count”
Allocation concealment: unclear
Blinding: participants and provider; assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 65% (330/507)
Length of follow up: 12 months
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Characteristics of included studies (Continued )
Participants Number analysed for primary outcome: 330; mean age 8.3 years
Inclusion criteria: all primary school children in grades 1, 2, and 3 in 2 schools in slum areas in Indonesia;
randomized according to Ascaris egg count and age
Exclusion criteria: children > 11; signs of puberty; signs of severe protein energy malnutrition
Interventions Multiple doses versus placebo
1. Pyrantel pamoate: 10 mg/kg
2. Pyrantel pamoate: 10 mg/kg repeated at 6 months
3. Albendazole: 400 mg
4. Albendazole: 400 mg repeated at 6 months
5. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Stool (Kato-Katz) prevalence and intensity
2. Weight
3. Height
4. Mid-upper arm circumference
5. Z-scores: weight-for-age, height for age, weight-for-height, and mid-upper arm circumference




Placebo group showed an unexplained drop in egg counts at the 3-month exam
Allocation concealment B – Unclear
Study Hall 2006
Methods Cluster-randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): unclear; 80 schools con-
taining 56,444 pupils randomized, and those from class 3 used in study
Length of follow up: 2 years
Participants Number analysed for primary outcome: 80 schools randomized containing 2659 children in class 3
Mean age: 104.5 months
Inclusion criteria: children from class 3 and born in 1990 of 80/81 schools in the Red River delta of north
Vietnam
Interventions Multiple doses versus placebo
1. Albendazole (GlaxoSmithKline): 400 mg every 6 months and 200,000 IU retinol after first 6 months only
2. Retinol: 200,000 IU after first 6 months followed by inert placebo every 6 months
Treatment strategy: randomized and treated all children
Outcomes Measured:
1. Hookworm, Trichuris, and Ascaris prevalence
2. Eggs/g faeces
3. Weight and height
Notes Location: Vietnam
Community category: 1
It is unclear what is meant by “randomization was adjusted so that there were equal numbers of schools in
each district of the study group”. It is also appears as if the analysis has not taken into account the effects of
cluster randomization
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Characteristics of included studies (Continued )
Allocation concealment D – Not used
Study Kloetzel 1982
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: participants only; provider and assessor unclear (described as double blind)
Inclusion of all randomized participants (number evaluable/number randomized): unclear (337 analysed)
Length of follow up: 10 months
Participants Number analysed for primary outcome: 337; unclear how many randomized; aged 1 to 8 years old
Inclusion criteria: enlisted from 9 rural communities in Pariquera-Acu state of S. Paulo
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Mebendazole: 100 mg twice per day for 3 days
2. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Weight
2. Height
3. Head, chest, and mid-arm circumference
4. Triceps skinfold
5. Stool egg counts (Kato-Katz)
Notes Location: Cameroon
Community category: 1
Results reported as changes in nutritional status grouped into 3 categories: improved, deteriorated, no change
(unclear on basis of which parameter), and proportions compared
Allocation concealment B – Unclear
Study Koroma 1996
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): 76% (187/247)
Length of follow up: 6 months
Participants Number analysed for primary outcome: 187
Inclusion criteria: selected (unclear how) urban and rural school primary children aged 6 to 10 years
Exclusion criteria: not stated
Interventions Single dose versus placebo
1. Albendazole: 400 mg
2. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Prevalence and intensity (arithmetic mean eggs/g)
2. Z-scores (no reference category stated): weight-for-height, weight-for-age, and height-for-age
Notes Location: Sierra Leone
Community category: 2
Allocation concealment B – Unclear
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Characteristics of included studies (Continued )
Study Kruger 1996
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): 72% (179/247)
Length of follow up: 11 months
Participants Number analysed for primary outcome: 74 aged 6 to 8 years
Inclusion criteria: 65 pupils in first year of school randomly selected from each of 5 primary schools; schools
included in a feeding scheme
Exclusion criteria: age > 9 years; current use of iron supplements; inclusion in an iron fortification trial;
infection (raised white cell count)
Interventions Multiple doses versus placebo
1. Albendazole: 2 x 200 mg repeated at 4 months, daily unfortified soup
2. Placebo: daily unfortified soup
Also: whole population
3/5 schools also allocated soup fortified with 20 mg elemental iron per day, and 100 mg vitamin C for
6 months; unclear whether this intervention was cluster randomized. All schools taking part in feeding
programme providing bread, soup, and peanut butter to all pupils
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
3. Mean change in haemoglobin post-treatment
Not included in review: other iron indices; stool egg counts (Visser filter method); Z-scores for weight-for-
age, height for age, and weight-for-height
Notes Location: South Africa
Community category: 3
In the Dickson 2000 Cochrane Review, the data were combined irrespective of the possible confounding
effects of iron allocation; data extracted for albendazole-iron placebo versus placebo-placebo groups only for
this review
Data stratified by baseline iron stores into 2 groups that were combined for meta-analysis
Allocation concealment B – Unclear
Study Kvalsvig 1991i
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): unclear
Length of follow up: 1 month
Participants Number analysed for primary outcome: unclear; age range unclear
Inclusion criteria: most severely infected 100 children in a primary school
Exclusion criteria: children with schistosomiasis
Interventions Single dose versus placebo
1. Mebendazole: 500 mg
2. Placebo
Treatment strategy: screened children then randomized and treated infected children
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Characteristics of included studies (Continued )
Outcomes 1. Cognition tests: card sorting task (coloured cards; cancellation task - striking out of letter ’s’ in text, number
done in a period)
Not included in review: height; weight at baseline; standardized using NCHS standards; stool examination
(intensity index designed for this trial); no growth outcomes reported that can be used in the review
Notes Location: South Africa
Community category: 1
No data used in meta-analysis since standard deviations not provided
Allocation concealment B – Unclear
Study Lai 1995
Methods Quasi-randomized controlled trial
Generation of allocation sequence: block assignment design by school, then by sex, then by presence of
worms as none, light, or moderate/heavy, and then by rank order of body weight in the group; used odd and
even numbers; in urban area the odd numbered children were assigned to treatment; in the peri-urban area
the even numbered children were assigned to the treatment group
Allocation concealment: unclear
Blinding: participants only
Inclusion of all randomized participants (number evaluable/number randomized): 89% (314/353)
Length of follow up: 2 years
Participants Number analysed for primary outcome: 314
Inclusion criteria: school children aged 8 who provided a stool sample
Exclusion criteria: concurrent illness; anthelminth treatment in previous 3 months
Interventions Multiple doses versus placebo
1. Mebendazole plus pyrantel: 100 mg mebendazole and 200 mg pyrantel every 3 months for 2 years
2. Placebo: every 3 months for 2 years
Treatment strategy: randomized and treated all children
Outcomes Measured:
1. Hookworm, Trichuris, and Ascaris prevalence
2. Eggs/g faeces
3. Weight and height
Notes Location: Malaysia
Community category: 1
No data used in meta-analysis since standard deviations not provided
Allocation concealment B – Unclear
Study Michaelsen 1985
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: unclear
Inclusion of all randomized participants (number evaluable/number randomized): 53% (121/228)
Length of follow up: 5 months
Participants Number analysed for primary outcome: 121 for growth outcomes; age range 5 to 14 years
Inclusion criteria: children from a school identified as having high prevalence of hookworm on the basis of
a previous survey
Exclusion criteria: children with height above 137 cm girls and 145 cm for boys since these were the upper
limits in the reference ranges
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Characteristics of included studies (Continued )
Interventions Single dose versus placebo
1. Tetrachloroethylene: 0.1 mL/kg (max 5 mL dose)
2. Placebo: children’s cough medicine
Treatment strategy: randomized and treated all children
Outcomes Measured:




5. Weight-for-height (WHO reference median 1983)
Reported:
1. Stool prevalence (graph) with 95% confidence intervals
2. Haemoglobin mean and difference (no SD)
3. Weight-for-height %, mean and difference (no SD)
Notes Location: Botswana
Community category: 1
Allocation concealment B – Unclear
Study Nokes 1992
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: participants; described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 73% (103/140)
Length of follow up: 2.25 months (9 weeks)
Participants Number analysed for primary outcome: 103; age range 9 to 12 years
Inclusion criteria: children from 3 schools in Mandeville; Trichuris egg counts > 1900, but low hookworm
counts on 2 occasions before the trial separated by 3 months
Exclusion criteria: twins; severe illness; physical handicaps; neurological disorders
Interventions Single dose versus placebo
1. Albendazole: 400 mg daily for 3 days (SmithKlineBeecham)
2. Placebo: identical
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. School attendance
2. Cognitive tests: digit span forwards/backwards; arithmetic and coding from Wechsler Intelligence Scale
for Children; fluency and listening comprehension from the Clinical Evaluation of Language functions; and
matching familiar figures test
Not included in review: stool egg counts at baseline and 10 days (prevalence and arithmetic mean); height
and weight (expressed as % NCHS standard) iron status; school attendance; IQ; socioeconomic status;
educational opportunity measures at baseline




There was an infected placebo group and an “uninfected control group”
Allocation concealment B – Unclear
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Characteristics of included studies (Continued )
Study Palupi 1997
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: participants; described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 97% (289/299)
Length of follow up: 9 weeks (2.25 months)
Participants Number analysed for primary outcome: 191
Inclusion criteria: children ages 2 to 5 years registered at village health centres
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Albendazole: 400 mg plus 30 mg elemental iron weekly
2. Elemental iron: 30 mg weekly
Treatment strategy: randomized and treated all children
Outcomes 1. Mean change in weight post-treatment
2. Mean change in height post-treatment
3. Mean change in haemoglobin post-treatment
4. Mean haemoglobin post-treatment
Not included in review: Z-scores for height-for-age, weight-for-age, and weight-for-height (NCHS reference)
Notes Location: Java, Indonesia
Community category: 2
Allocation concealment B – Unclear
Study Rousham 1994
Methods Cluster-randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: participants described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 94% (1402/1476)
Length of follow up: 18 months
Participants Number analysed for primary outcome: 1402
Inclusion criteria: children ages 2 to 6 years from 13 villages surrounding a mother and child health centre;
subgroup living in 8 villages within waking distance of health centre analysed for additional outcomes
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Mebendazole: 500 mg (Janssen) every 2 months
2. Placebo
3. Pyrantel pamoate and mebendazole: initial dose of 10 mg/kg pyrantel pamoate (Combantrin, Pfizer, UK)
then mebendazole 500 mg bimonthly for 8 months (4 doses)
Treatment strategy: randomized and treated all children
Outcomes 1. ANOVAs for change in Z-scores for Z-scores for height-for-age, weight-for-age, and weight-for-height
(NCHS reference)
2. Change in mid-upper arm circumference at 6, 12, and 18 months (no SD)
3. Other outcomes measured but not reported: height; weight; stool examination for prevalence and intensity
in subgroup (eggs/g: modified sedimentation technique); subgroup also analysed for intestinal permeability,
albumin, alpha-1-antichymotrypsin, total protein every 2 months
Notes Location: Bangladesh
Community category: 1
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Characteristics of included studies (Continued )
No adjustment made for cluster randomization
Allocation concealment B – Unclear
Study Sarkar 2002
Methods Randomized controlled trial
Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: participants described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 94% (81/85)
Length of follow up: 4 months (16 weeks)
Participants Number analysed for primary outcome: 81
Inclusion criteria: children ages 2 to 12 living in Mirpur slum infected with Ascaris
Exclusion criteria: none stated
Interventions Single dose versus placebo
1. Pyrantel pamoate: 11 mg/kg (Combantrin, Pfizer, Bangladesh)
2. Placebo
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Mean change in weight post-treatment
2. Mean weight post-treatment
3. Mean change in height post-treatment
4. Mean height post-treatment
Not included in review: median % weight-for-age, weight-for-height, and height-for-age
Notes Location: Bangladesh
Community category: 1
Allocation concealment B – Unclear
Study Simeon 1995
Methods Randomized controlled trial
Generation of allocation sequence: random-numbers table
Allocation concealment: unclear
Blinding: participants described as double blind; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 96% (392/407)
Length of follow up: 6.5 months (26 weeks)
Participants Number analysed for primary outcome: 392; age range 6 to 12 years
Inclusion criteria: children in grades 2 to 5 of 14 schools in Jamaica with intensities of Trichura > 1200 eggs/g
Exclusion criteria: children with mental handicaps identified by their teachers
Interventions Multiple doses versus placebo
1. Albendazole: 800 mg (400 mg in each of 2 days), repeated at 3 months and 6 months
2. Identical placebo
Treatment strategy: screened children then randomized and treated infected children
Outcomes 1. Main study (264 children)
Wide range achievement test: reading, arithmetic, and spelling subtests; school attendance from children with
class registers pre- and post-intervention, height-for-age Z-score, body mass index pre- and post-intervention
2. Subgroup 1 (189 infected children from original population)
Digit span; verbal fluency test; visual search; number choice; French vocabulary learning
3. Subgroup 2 (97 children from grade 5)
French learning; digit spans (forward and backward); Corsi block span; verbal fluency; picture search; silly
sentences
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Characteristics of included studies (Continued )
Other outcomes measured but not reported: stool at baseline and at 8 weeks after second treatment round
(Kato): prevalence and intensity, weight, height, Z-scores (NCHS standard)
Notes Location: Jamaica
Community category: 1
Allocation concealment B – Unclear
Study Stephenson 1989
Methods Randomized controlled trial
Generation of allocation sequence: “at random within sex”
Allocation concealment: unclear
Blinding: participants and assessor only; provider unclear
Inclusion of all randomized participants (number evaluable/number randomized): 88% (150/171)
Length of follow up: 6 months
Participants Number analysed for primary outcome: 150
Inclusion criteria: all available children in lower grades (standards 1 and 2) in Mvindeni Primary School,
Kwale district (unscreened); subgroup of 36 boys chosen; haemoglobin > 8; willing to co-operate in physical
tests; pre-pubertal
Exclusion criteria: haemoglobin < 8
Interventions Single dose versus placebo
1. Albendazole: 2 x 200 mg (SmithKline and French)
2. Placebo: identical
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
7. Mean triceps skinfold thickness
8. Mean change in triceps skinfold thickness
9. Mean subscapular skinfold thickness
10. Mean change in subscapular skinfold thickness
Not included in review: all above converted to % median for sex and age; prevalence and mean egg counts
(arithmetic and geometric means); Harvard Step Test heart rates and score for subgroup
Notes Location: Kenya
Community category: 1
Allocation concealment B – Unclear
Study Stephenson 1993
Methods Randomized controlled trial
Generation of allocation sequence: “at random within sex by descending hookworm egg count”
Allocation concealment: unclear
Blinding: participants and assessor only; provider unclear
Inclusion of all randomized participants (number evaluable/number randomized): 86% (284/328)
Length of follow up: 3.6 months (subgroup) and 8.2 months (main study)
Participants Number analysed for primary outcome: 284
Inclusion criteria: all school children (unscreened) in grades 1 to 5 in Mvindeni Primary School
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Characteristics of included studies (Continued )
Subgroup (53 analysed) of 60 boys chosen because haemoglobin > 80 g/L, willing to cooperate in physical
tests and appetite tests, pre-pubertal, infected with at least 1 of helminths (screened), hookworm < 20,000
eggs/g; hookworm or Trichuris count > 1000 eggs/g or Ascaris > 4000 eggs/g
Exclusion criteria: Severe anaemia (haemoglobin < 75 g/L)
Interventions Multiple doses versus placebo
1. Albendazole (single dose) plus placebo: 600 mg (3 x 200 mg) SmithKline Beecham at outset, identical
placebo at 3.6 months
2. Albendazole (multiple doses): single dose 600 mg repeated at 3.6 months
3. Placebo: identical placebo
Treatment strategy: randomized and treated all children (but infected children for appetite/activity outcomes)
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. Mean mid-upper arm circumference
6. Mean change in mid-upper arm circumference
7. Mean triceps skinfold thickness
8. Mean change in triceps skinfold thickness
9. Mean subscapular skinfold thickness
10. Mean change in subscapular skinfold thickness
11. Mean haemoglobin post-treatment
12. Mean change in haemoglobin post treatment
Not included in review: prevalence, eggs/g: geometric and arithmetic mean; converted to percentage of
median for age and sex using NCHS references; % weight-for-age, % height for age; % weight-for-height; %
arm circumference for age; % triceps for age; % subscapular for age; Harvard Step Test; appetite (self-rating
and snack consumed intake in kilojoules); haemoglobin
Notes Location: Kwale, Kenya
Community category: 1
Allocation concealment B – Unclear
Study Stoltzfus 1997
Methods Cluster-randomized controlled trial
Generation of allocation sequence: from each of the 4 districts, 3 schools randomly selected and then allocated
Allocation concealment: unclear
Blinding: participants only; provider and assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 84% (3063/3605)
Length of follow up: 12 months
Participants Number analysed for primary outcome: 3063; mean age 10.5 years
Inclusion criteria: children in grades 1 to 5 from 12 randomly selected schools on Pemba island; only grades
1 to 4 included in evaluation of nutritional effect
Exclusion criteria: none stated
Interventions Multiple doses versus placebo
1. Mebendazole: 500 mg twice yearly
2. Mebendazole: 500 mg 3 times a year
3. Placebo
Treatment strategy: randomized and treated all children
Outcomes 1. Weight gain
2. Height gain
3. Change in haemoglobin at 12 months
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Characteristics of included studies (Continued )
Estimates are provided from multiple regression models taking into account various baseline differences
for 2 subgroups above and below 10 years old. Unadjusted outcomes not presented. (These 2 groups were
combined in the Dickson 2000 Cochrane Review.)
Other outcomes measured but not reported: micronutrient status (blood) for protoporphyrin and serum
ferritin; stool egg count (Kato-Katz); Z-scores for height-for-age and weight-for-height; body mass index
Notes Location: Zanzibar, Tanzania
Community category: 1
Appropriate adjustment made for cluster randomization using general estimating equation
Allocation concealment B – Unclear
Study Stoltzfus 2001
Methods Randomized control trial (factorial design)
Generation of allocation sequence: “blocks of 4”
Allocation concealment: pills in bottles with unique treatment codes, assigned by 1 investigator, codes kept
in sealed envelopes
Blinding: participants and provider; assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 52% (359/684 = 52%)
Length of follow up: 12 months
Participants Number analysed for primary outcome: 359 in mebendazole arm aged 6 to 59 months
Inclusion criteria: all children in Kengeja village, with age reported as 3 to 56 months by parents; 3 months
before planned start of trial (pre-school children)
Exclusion criteria: severe anaemia (< 70 g/L)
Interventions Multiple doses versus placebo
1. Mebendazole: 500 mg given every 3 months at home visits
2. Placebo: identical
Treatment strategy: randomized and treated all children
Both groups also received: 0.5 mL ferrous sulfate (20 mg/mL); 10 mg iron daily for 1 year or placebo as per
factorial design
Outcomes 1. Cognitive outcomes: motor and language development by parents reporting gross motor and language
milestones using scoring system developed specifically for the trial
2. Anthropometric measures presented in a stratified manner: (< 30 months, > 30 months), and presented
as proportion of children with small arm circumference, mild wasting, and stunting
3. Proportion of children with poor appetite, and proportion with severe anaemia are presented for the whole
group
4. Iron indices (not disaggregated, independent of the iron randomization)
Not included in review: prevalence and egg counts (no SD/SEM); motor and language scores (results of
multiple regression and correlations; raw data not reported)
Others measured but not reported: stool (Kato-Katz); weight; height; haemoglobin; malaria film; ferritin;
appetite as reported by mothers
Notes Location: Zanzibar, Tanzania
Community category: 2
Factorial design, with households randomized to iron, random allocation of mebendazole by child, stratified
by iron allocation and age grouped households. An iron with mebendazole treatment term was tested in all
regression models, but it did not reach significance
Allocation concealment A – Adequate
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Characteristics of included studies (Continued )
Study Sur 2005
Methods Randomized controlled trial
Generation of allocation sequence: computer-generated random numbers sequence
Allocation concealment: identical coded bottles
Blinding: participants, provider, and assessor
Inclusion of all randomized participants (number evaluable/number randomized): 97% (683/702)
Length of follow up: 12 months
Participants Number analysed for primary outcome: 683
Inclusion criteria: all children aged 2 to 5 in slum area of Tiljala identified and enrolled
Exclusion criteria: major illnesses; birth defects; and unwillingness to participate
Interventions Multiple doses versus placebo
1. Albendazole: 400 mg in a vitamin B complex base liquid; repeated at 6 months
2. Placebo: vitamin B complex base
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment (presented graphically)
Other outcomes measured but not reported: stool samples from random sample of 30% (formalin concen-
tration technique) for prevalence of Ascaris; weight-for-age; diarrhoeal episodes
Notes Location: India
Community category: 2
Allocation concealment A – Adequate
Study Watkins 1996
Methods Randomized controlled trial
Generation of allocation sequence: “stratified by gender and age”
Allocation concealment: unclear
Blinding: participants and provider; assessor unclear
Inclusion of all randomized participants (number evaluable/number randomized): 90% (226/250)
Length of follow up: 6 months
Participants Number analysed for primary outcome: 226 for growth outcomes, reduced for cognitive outcomes; age 7 to
12 years
Inclusion criteria: children attending grades 1 to 4 in primary schools in the Guatemala highlands
Exclusion criteria: > 12 years; deworming medicine in last year
Interventions Multiple doses versus placebo
1. Albendazole: 2 x 200 mg at baseline and 12 weeks
2. Placebo: identical at baseline and 12 weeks
Treatment strategy: randomized and treated all children
Outcomes 1. Mean weight post-treatment
2. Mean change in weight post-treatment
3. Mean height post-treatment
4. Mean change in height post-treatment
5. School performance: attendance rates of children actively attending school, dropout rates
6. Mean mid-upper arm circumference
7. Mean change in mid-upper arm circumference
8. Cognitive tests: Interamerican vocabulary test, Interamerican reading test, Peabody picture vocabulary test
Not included in review: egg counts (Kato-Katz: arithmetic and geometric mean); Z-scores (NCHS-CDC-
WHO reference) for weight-for-age, change in weight-for-age, height, change in height, height-for-age,
change in height-for-age, weight-for-height, and change in height-for-age
36Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Notes Location: Guatemala
Community category: 1
Allocation concealment B – Unclear
Study Willett 1979
Methods Randomized controlled trial
Generation of allocation sequence: random-numbers table; “stratified by sex and age”
Allocation concealment: unclear
Blinding: described as double blind; participants and assessor only; provider unclear
Inclusion of all randomized participants (number evaluable/number randomized): 78% (268/341)
Length of follow up: 12 months
Participants Number analysed for primary outcome: 268; age range 6 to 91 months
Inclusion criteria: pre-school children from Ubiri village who attended clinic and produced a stool sample
Exclusion criteria: none stated
Interventions Multiple doses
1. Levamisole syrup: 2.5 mg/kg every 3 months
2. Flavoured sucrose syrup: every 3 months
Treatment strategy: randomized and treated all children
Outcomes 1. Growth rates in both groups, and subgroup of those infected; these have been corrected for various factors
using analysis of covariance (unadjusted data are not reported and the growth rates are not presented with
any measure of variance)




Allocation concealment B – Unclear
CI: confidence interval; Community category: a measure of the prevalence and intensity of infection (see Table 02); NCHS: National Center for Health
Statistics: SD: standard deviation; SEM: standard error of the mean
Characteristics of excluded studies
Study Reason for exclusion
Bhargava 2003 Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Boivin 1993 Factorial-designed randomized controlled trial with children allocated to deworming and iron supplementation,
and in which the analysis compares the results for the levamisole and iron group against all the other groups
combined. (Included in the Dickson 2000 Cochrane Review.)
Cooper 2006 Study of allergy with no nutritional or cognitive outcomes
Cowden 2000 Not a randomized controlled trial
Diouf 2002 Intervention comprised mebendazole, vitamin A, and iron supplementation metronidazole as a combined inter-
vention versus placebo
Evans 1986 Treatments randomized, but some placebo groups accessed treatment. Analysis was by the treatment received,
and randomization was ignored. (Included in the Dickson 2000 Cochrane Review.)
Fernando 1983 2 villages allocated to treatment or no treatment on the basis of a coin toss. Essentially a cluster-randomized
trial with 2 large clusters. (Included in the Dickson 2000 Cochrane Review, which reported that no conclusions
could be drawn from the results due to selective reporting.)
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Characteristics of excluded studies (Continued )
Friis 2003 Combined treatment regimen albendazole for geohelminths and praziquantel for Schistosoma mansoni versus
placebo
Gupta 1982 Children randomly divided into 4 groups, “taking care that age distribution was similar in each group”. The 4
groups were then allocated 1 of 4 different single treatment regimens; no details given. We excluded trials in
communities with only 2 units of allocation
Hadidjaja 1998 Cluster-randomized controlled trial with 2 units of allocation to mebendazole and placebo. Authors stated that
there were differences in environmental sanitary conditions in the clusters. (Included in the Dickson 2000
Cochrane Review, but it was noted that the groups were not comparable and there was high loss to follow up.)
Jinabhai 2001a Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Jinabhai 2001b Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Kvalsvig 1991ii Incomplete data on the number of children in each arm of the trial. The researchers were unable to re-test
children due to major floods in the area
Miguel 2004 Treatment regimen comprised of albendazole for geohelminths and praziquantel against schistosomiasis versus
placebo
Pollitt 1991 Not described as randomized; conference proceedings
Taylor 2001 Treatment regimen albendazole for geohelminths and praziquantel for Schistosoma haematobium versus placebo
Thein-Hlaing 1991 3/11 intervention villages were not randomly allocated, and unclear how intervention and control villages were
allocated as there is a large imbalance (8 intervention and 13 non-intervention villages)
Yang 2003 Did not consider growth or cognitive outcome measures
Characteristics of ongoing studies
Study Alam 2006
Trial name or title “Relative efficacy of two regimens of ante-helminthic treatment”
Participants Total enrolment: 200
Inclusion criteria: age 2 to 5 years; not suffering from serious chronic illness; stool test positive for soil-trans-
mitted helminths; not taken any anthelminthic drug in previous 6 months; parents/guardian agree their child’s
participation
Exclusion criteria: age < 2 years and > 5 years; stool test negative for any intestinal helminth; suffering from
serious chronic illness; parents/guardian not willing to give consent for their child’s participation; if he/she
receives any anthelminthic drug after survey but before the study interventions
Interventions 1. Conventional treatment of 400 mg of albendazole in a single dose at 6-month interval
2. Intervention group: 400 mg of albendazole in a single-dose treatment at 3-month interval
Outcomes PRIMARY
1. To determine the relative efficacy of de-worming at every 3 months versus every 6 month single dose of
albendazole treatment
SECONDARY
2. To compare additional morbidity information such as diarrhoeal diseases, respiratory tract infections, nutri-
tional status and E. histolytica associated morbidity between 2 groups
Starting date Not yet recruiting
Contact information Mohammad M Alam MBBS, Principal Investigator, ICDDR,B: Centre for Health and Population Research,
masud_icddrb@yahoo.com
Notes ClinicalTrials.gov identifier: NCT00367627
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Characteristics of ongoing studies (Continued )
Sources of support: International Centre for Diarrhoeal Disease Research, Bangladesh (sponsor)
Study Lucknow ongoing




Starting date Details unavailable
Contact information Details unavailable
Notes Details unavailable
Study Stoltzfus 2004
Trial name or title “Effects of intestinal helminth infections in early childhood on immune response, inflammation, anaemia and
malnutrition”
Participants Expected enrolment: 2500
Inclusion criteria: 6 to 24months of age; informed consent; residing in selected communities based on geographic
catchment area
Exclusion criteria: haemoglobin < 70 g/L; refusal of informed consent
Interventions 1. Mebendazole
2. Identical-looking but inert placebo
Outcomes PRIMARY
1. Haemoglobin < 70 g/L
2. Mid-upper arm circumference <-2 Z scores of international reference
3. Maternal report of anorexia
SECONDARY
4. Weight-for-height <-1 Z scores of international reference
5. Height-for-age <-2 Z scores on international reference
6. Inflammation
Starting date 1 January 2004
End of follow up date: 31 March 2006
Contact information Ms Rebecca J Stoltzfus, Cornell University
Division of Nutritional Sciences, rjs62@cornell.edu
Notes ISRCTN: 83988447
Sources of support: Burroughs Wellcome Initiative; Wellcome Trust; Cornell University, USA (sponsor)
A D D I T I O N A L T A B L E S
Table 01. Community diagnosis categories and recommended treatment strategies (WHO 2002)
Community category Prevalenceˆ Proportionˆˆ School intervention
1. High prevalence or high intensity > 70% > 10% Targeted treatment of school-age children 2 to
3 times per year
2. Moderate prevalence and low intensity > 50% but < 70% < 10% Targeted treatment of school-age children once
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Table 01. Community diagnosis categories and recommended treatment strategies (WHO 2002) (Continued )
Community category Prevalenceˆ Proportionˆˆ School intervention
per year
3. Low prevalence and low intensity < 50% < 10% Selective treatment
ôf any worm infection
ˆôf moderate to heavy infections
Table 02. Detailed search strategies
Search set CIDG SRˆ CENTRAL MEDLINEˆˆ EMBASEˆˆ LILACSˆˆ











3 Necator americanus Necator americanus Necator americanus Necator americanus Necator americanus











6 trichuris trichuris trichuris trichuris trichuris
7 Strongyloid* Strongyloid* Strongyloid* Strongyloid* Strongyloid*
8 albendazole hookworm* hookworm* hookworm$ 1-7/OR
9 mebendazole roundworm* roundworm* roundworm$ albendazole
10 piperazine pinworm* pinworm* pinworm$ mebendazole
11 levamisole whipworm* whipworm* whipworm$ piperazine
12 pyrantel 1-11/OR 1-11/OR 1-11/OR levamisole
13 tiabendazole albendazole albendazole albendazole pyrantel
14 - mebendazole mebendazole mebendazole tiabendazole
15 - piperazine piperazine piperazine 9-14/OR
16 - levamisole levamisole levamisole 8 and 15
17 - pyrantel pyrantel pyrantel Limit 16 to human
18 - tiabendazole tiabendazole tiabendazole -
19 - 13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
13 or 14 or 15 or 16
or 17 or 18
-
20 - 12 and 19 12 and 19 12 and 19 -
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Table 02. Detailed search strategies (Continued )











upper case: MeSH or
EMTREE heading;
lower case: free text
term
Table 03. Cluster-randomized controlled trials
Trial Cluster No. clusters Adjustmentˆ
Alderman 2006 Parishes 48 Not adjusted (correspondence with author)
Awasthi 1995 Urban slums 50 Means of cluster means
Awasthi 2001 Urban slums 124 Means of cluster means
Hall 2006 Schools 80 Unclear
Rousham 1994 Villages 13 No
Stoltzfus 1997 Schools 12 General estimating equation
ˆfor cluster randomization
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Table 04. Trials with incomplete statistical data sets
Randomization type Dose schedule Trial Intervention Results
Individual Single dose Beach 1999 Albendazole A nutritional benefit of treatment was not
detectable after 4 months for the entire
study population (853 participants, no
figures provided). Stratification by infection
demonstrated small positive effects in the
treatment group for some anthropometric
outcomes. In Ascaris-infected children (51),
height gain was 0.62 cm greater than placebo
in the combination treatment group (P = 0.01)
at 4 months. In Trichuris-infected children
(158), height gain was 0.56 kg greater than
placebo in the combination treatment group
(P = 0.01) at 4 months
Individual Single dose Fox 2005 Albendazole No results provided for whole study
population. Results for height and weight
only presented in the narrative for subgroups
infected with hookworm and Ascaris: no
significant anthropometric changes detected
(no figures quoted). In those infected with
Trichuris, weight gain was greater in the
albendazole group (difference compared to
placebo 0.28 kg, P = 0.038)
Individual Single dose Greenberg 1981 Piperazine citrate Treatment group tended to show worse
growth than placebo. Comparison showed
no significant difference for all measured
anthropometric variables for the total group
and for subgroups defined by severity of
infection (no figures provided)
Individual Single dose Kloetzel 1982 Mebendazole No significant difference was found between
the groups. Results reported as the proportion
of treatment or control group that improved,
deteriorated, or experienced no change.
Unclear which anthropological measures were
used in this categorization process. Proportions






























































































































Table 04. Trials with incomplete statistical data sets (Continued )
Randomization type Dose schedule Trial Intervention Results
different between trial arms (improved: 51%
in mebendazole group vs 49% in control;
deteriorated: 35% in mebendazole group
vs 33% in control; no change: 14% in
mebendazole group vs 18% in control; no
significance test results quoted)
Individual Single dose Koroma 1996 Albendazole Significant increases in weight-for-height,
weight-for-age, and height-for-age Z-scores
recorded in rural and urban treatment groups
at 6 months
Mean increase in rural treatment group
compared to placebo: weight-for-height Z-
score 0.28 (SE 0.17) P < 0.05; weight-for-age
Z-score 1.04 (SE 0.03) P < 0.05; and height-
for-age Z-score 0.83 (SE 0.03) P < 0.001
Mean increase in urban treatment group
compared to placebo: weight-for-height Z-
score 1.04 (SE 0.07) P < 0.05; weight-for-age
Z-score 1.02 (SE 0.09) P < 0.001; and height-
for-age Z-score 1.01 (SE 0.02) P <0.05
Significant increases in weight-for-height,
weight-for-age, and height-for-age Z-scores
recorded in rural and urban treatment groups
at 6 months (mean increase in rural treatment
group compared to placebo): weight-for-
height Z-score 0.28 (SE 0.17) P < 0.05;
weight-for-age Z-score 1.04 (SE 0.03) P <
0.05; and height-for-age Z-score 0.83 (SE
0.03) P < 0.001
Mean increase in urban treatment group
compared to placebo: weight-for-height Z-
score 1.04 (SE 0.07) P < 0.05; weight-for-age
Z-score 1.02 (SE 0.09) P < 0.001; and height-
for-age Z-score 1.01 (SE 0.02) P < 0.05






























































































































Table 04. Trials with incomplete statistical data sets (Continued )
Randomization type Dose schedule Trial Intervention Results
for haemoglobin (tetrachloroethylene 0.22
g/100 mL vs placebo 0.09 g/100 mL; quoted
as nonsignificant) or weight for height at 5
months (tetrachloroethylene -1.3% of WHO
reference mean vs placebo -0.4%; quoted as
nonsignificant)
Individual Single dose Nokes 1992 Albendazole Growth measured but not reported: 9 weeks
cited as too short a follow-up period to
demonstrate a change
Individual Multiple dose trials > 1 year Lai 1995 Mebendazole plus pyrantel No difference in height or weight between
treatment and control group at the end of
2-year follow up. Standard deviations not
provided. Results stratified for males and
females:
Females: change in height in treatment arm
12.2 cm vs change in height in placebo arm
12.4 cm; change in weight in treatment arm
5.6 kg vs change in weight in placebo arm 5.6
kg
Males: change in height in treatment arm
11.8 cm vs change in height in placebo arm
11.4cm; change in weight in treatment arm
5.7 kg vs change in weight in placebo arm 4.7
kg
Individual Multiple dose trials < 1 year Hadju 1997 Pyrantel pamoate
Albendazole
No significant differences detected between
treatment groups on basis of multivariate
analyses controlling for age, sex, and ’times’:
Change in weight-for-age Z-score: placebo
0.02; pyrantel 1 x treatment 0.03; pyrantel 2 x
treatments 0.08; albendazole 1 x treatment -
0.10; albendazole 2 x treatments 0.01
Change in height-for-age Z-score: placebo
0.01; pyrantel 1 x treatment 0.00; pyrantel 2 x






























































































































Table 04. Trials with incomplete statistical data sets (Continued )
Randomization type Dose schedule Trial Intervention Results
0.07; albendazole 2 x treatments 0.01
Change in weight-for-height Z-score: placebo
0.02; pyrantel 1 x treatment 0.08; pyrantel 2 x
treatments 0.05; albendazole 1 x treatment -
0.07; albendazole 2 x treatments 0.03
Change mid-arm circumference Z-score:
placebo -0.09; pyrantel 1 x treatment -0.11;
pyrantel 2 x treatments -0.11; albendazole 1 x
treatment -0.07; albendazole 2 x treatments -
0.01
Individual Multiple dose trials < 1 year Simeon 1995 Albendazole No significant difference in any reported
outcome for whole group:
Height-for-age Z-score at baseline in treatment
group -0.48 (0.95) and in placebo group -0.39
(0.90). At follow up in treatment group -0.48
(0.97) and in placebo group -0.41 (0.89)
Body mass index (kg/m2) at baseline in
treatment group 15.3 (1.3) and in placebo
group 15.5 (1.3). At follow up in treatment
group 15.6 (1.3) and in placebo group 15.8
(1.4)
Individual Multiple dose trials < 1 year Stoltzfus 2001 Mebendazole Mebendazole is reported as significantly
reducing the prevalence of mild wasting
malnutrition in a subgroup of children aged
< 30 months only (adjusted odds ratio for
mebendazole 0.38 (95% CI 0.16 to 0.90) for
weight-for-height Z-score < -1). Mebendazole
is reported as significantly reducing the
prevalence of poor appetite across the whole
group (adjusted odds ratio for mebendazole
0.52 (95% CI 0.30 to 0.89) for weight-
for-height Z-score < -1). Mebendazole had
no impact on iron indices. Adjusted effect
on motor scores had a tendency to favour





























































































































Table 04. Trials with incomplete statistical data sets (Continued )
Randomization type Dose schedule Trial Intervention Results
Individual Multiple dose trials < 1 year Willett 1979 Levamisole No statistical difference in growth rates in
terms of height and weight between the 2
groups. Growth rates presented are adjusted
for a number of variables. Weight gain
(kg/year) in levamisole group 2.08 vs 1.92
in placebo group (P = 0.06). Height gain
(cm/year) in levamisole group 7.58 vs 7.73 in
placebo group (no significance quoted)
Cluster-randomized trial (12 schools) Multiple dose trials < 1 year Stoltzfus 1997 Mebendazole Weight gain: in a subgroup of under 10
year olds, the twice-yearly treated group
experienced significantly greater weight gain
(kg) compared to control (2.38 (SE 0.08)
vs 2.11 (SE 0.08), P < 0.05). In the thrice
yearly treatment group the difference was not
significant (2.31 (SE 0.08) vs 2.11 (SE 0.08),
no P value stated)
Height gain: in under 10 year olds the thrice-
yearly treated group experienced significantly
greater height gain (cm) compared to control
(4.59 (SE 0.07) vs 4.29 (SE 0.07), P < 0.01).
In the twice-yearly treatment group the
difference in height gain was not significant
(4.42 (SE 0.07) vs 4.29 (SE 0.07), no P value
stated). There were no significant differences
found in the subgroup of children aged over
10 years
Haemoglobin change: deworming had no
effect on haemoglobin change in an adjusted
analysis presented for the whole study group
(g/L): control 11.3 (SE 1.7); twice-yearly
treatment group 10.3 (SE 1.7); and thrice-
yearly group 12.7 (SE 1.7)
Cluster-randomized trial (50 parishes) Multiple dose trials > 1 year Alderman 2006 Albendazole Trial authors reported average weight gain
over a period of up to 3 years for individual






























































































































Table 04. Trials with incomplete statistical data sets (Continued )
Randomization type Dose schedule Trial Intervention Results
and the 24 control parishes. In the treatment
parishes, the mean (SD) weight gain (g) 2413
(2536) and in the control parishes 2259
(2474) (Alderman 2006; Table 02). Trial
authors confirmed that these results were not
adjusted to take into account clustering. In
table 3 of the same paper, a regression analysis
is adjusted for sampling effects
Cluster-randomized trial (80 schools) Multiple dose trials > 1 year Hall 2006 Albendazole Trial authors reported no difference in final
and change in weight and height. Mid-upper
arm circumference and subscapular skinfold
thickness improved significantly in the control
group compared to the albendazole group.
These results do not appear to have been
adjusted for cluster randomization. The
results that show no effect, however, will not
remain nonsignificant even after appropriate
adjustment, though the confidence intervals
may change
Cluster-randomized trial (13 villages) Multiple dose trials > 1 year Rousham 1994 Mebendazole ANOVAS of the change in Z-scores revealed
no significant improvement with treatment.
Change in weight-for-age and weight-for-
height Z-scores were significantly worse
in the treatment group. Height-for-age Z-
score (mebendazole 0.25 v 0.17 in placebo
group, P ’nonsignificant’), weight-for-age Z-
score (mebendazole 0.03 vs 0.12 in placebo
group, P < 0.05), weight-for-height Z-score
(mebendazole -0.25 vs -0.05 in placebo group,
P < 0.001), and mid-upper arm circumference
were presented (mebendazole 0.33 vs 0.23 in






























































































































Table 05. Methodological quality assessment
Trial Design Sequenceˆ Concealmentˆ Blinding Inclusionˆ
Adams 1994 Individual Unclear Unclear Participants only; provider and
assessor unclear
Adequate
Awasthi 2000 Individual Inadequate Inadequate Participants only; provider not
blinded; assessor unclear
Adequate
Beach 1999 Individual Adequate Unclear Participants, provider, and assessors Inadequate
Donnen 1998 Individual Unclear Unclear Unclear Inadequate
Dossa 2001 Individual Unclear Unclear Participants, provider, and assessor
unclear; described as double blind
Inadequate
Fox 2005 Individual Adequate Adequate Described as double blind; provider
unclear
Adequate
Freij 1979i Individual Inadequate Unclear Described as double blind Adequate
Freij 1979ii Individual Inadequate Unclear Described as double blind Adequate
Garg 2002 Individual Adequate Adequate Assessor; participants unclear;
provider not blinded
Adequate
Greenberg 1981 Individual Unclear Unclear Participants; described as double
blind; provider and assessor unclear
Inadequate
Hadju 1996 Individual Unclear Unclear Participants; described as double
blind; provider and assessor unclear
Inadequate
Hadju 1997 Individual Unclear Unclear Participants and provider; assessor
unclear
Inadequate
Kloetzel 1982 Individual Unclear Unclear Participants; provider and assessor
unclear; described as double blind
Unclear
Koroma 1996 Individual Unclear Unclear Unclear Inadequate
Kruger 1996 Individual Unclear Unclear Unclear Inadequate
Kvalsvig 1991i Individual Unclear Unclear Unclear Unclear
Lai 1995 Individual Inadequate Unclear Participants only Inadequate
Michaelsen 1985 Individual Unclear Unclear Unclear Inadequate
Nokes 1992 Individual Unclear Unclear Participants described as double
blind; provider and assessor unclear
Inadequate
Palupi 1997 Individual Unclear Unclear Described as double blind Adequate
Sarkar 2002 Individual Unclear Unclear Described as double blind Adequate
Simeon 1995 Individual Adequate Unclear Participants described as double
blind; provider and assessor unclear
Adequate
Stephenson 1989 Individual Unclear Unclear Participants and assessor; provider
unclear
Inadequate
Stephenson 1993 Individual Unclear Unclear Participants and assessor; provider
unclear
Inadequate
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Table 05. Methodological quality assessment (Continued )
Trial Design Sequenceˆ Concealmentˆ Blinding Inclusionˆ
Stoltzfus 2001 Individual Unclear Adequate Participants, provider, and assessor
unclear
Inadequate
Sur 2005 Individual Adequate Adequate Participants, provider, and assessor Adequate
Watkins 1996 Individual Unclear Unclear Participants and provider; assessor
unclear
Adequate
Willett 1979 Individual Adequate Unclear Participants and assessor; provider
unclear; described as double blind
Inadequate
Alderman 2006 Cluster Adequate Unclear None Inadequate
Awasthi 1995 Cluster Unclear Unclear Unclear Inadequate
Awasthi 2001 Cluster Unclear Unclear None Inadequate
Hall 2006 Cluster Unclear Unclear Unclear Unclear
Rousham 1994 Cluster Unclear Unclear Participants described as double
blind; provider and assessor unclear
Adequate
Stoltzfus 1997 Cluster Unclear Unclear Participants; provider and assessor
unclear
Inadequate
ˆGeneration of allocation sequence,
allocation concealment, and
inclusion of all randomized
participants
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Table 06. Trials evaluating school performance or cognition
Trial Follow up Participants Intervention Outcome measures Results
Awasthi 2000 2 years Indian children aged 1.5 to








No difference in development
between treatment groups
in terms of proportion with
“normal” development
Hall 2006 2 years Children from class 3 and
born in 1990 of 80/81
schools in the Red River delta
of north Vietnam
Community category: 1





differences in test results
at start or end of study.
These results do not appear







Kvalsvig 1991i 1 month South African children with
most severe worm infestations
in a school Number analysed:
39/100
Community category: 1
Single dose of mebendazole
versus placebo
Card sorting task; cancellation
task (number of letter ’s’ in
text deleted in a time period)
Changes in cognitive scores
are not clearly reported since
“the dose of mebendazole was
inadequate to free children
from infection”
Nokes 1992 2.25 months Jamaican children aged 9
to 12 years with Trichuris
egg counts > 1900, but
low hookworm counts on
2 occasions separated by 3
months before the trial
Number analysed: 103/140
Community category: 1
Single dose of albendazole
versus placebo








matching familiar figures test
Mean test scores pre- and
post-intervention presented
with confidence intervals
No comment made on
significance of unadjusted
data
Results of multiple regression
suggest a greater improvement
in treated children in
3/10 tests (fluency, digit
span forwards, digit span
backwards)






























































































































Table 06. Trials evaluating school performance or cognition (Continued )
Trial Follow up Participants Intervention Outcome measures Results
to 12 in grades 2 to 5 with
intensities of Trichura > 1200
eggs/g
Community category: 1
versus placebo Wide range achievement
test: reading, arithmetic,
and spelling subtests; school
attendance from children
with class registers pre- and
post-intervention
2. Subgroup 1 (189 children
189 infected children from
original population)
Digit span; verbal fluency
test; visual search; number
choice; French vocabulary
learning
3. Subgroup 2 (97 children
from grade 5)
French learning; digit spans
(forward and backward);
Corsi block span; verbal
fluency; picture search; silly
sentences
in any reported outcome
measure
2. Subgroup 1: no significant
effect on any of the outcome
measures
3. Subgroup 2: no significant
improvement with treatment
in any of the tests was
found in multiple regression
modelling
Stoltzfus 2001 1 year Zanzibari children reported
as 3 to 56 months, 3 months







reporting gross motor and
language milestones using
scoring system developed
specifically for the trial
Unadjusted data not reported
Treatment had no significant
effect on motor or language
development
Watkins 1996 6 months Guatemalan children aged 7
to 12 years attending grades 1
to 4 in primary schools
Number analysed: 226/250
Community category: 1









reported as unadjusted scores
No difference in any of the
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A N A L Y S E S





participants Statistical method Effect size
01 Weight (kg) 9 2448 Weighted Mean Difference (Random) 95% CI 0.34 [0.05, 0.64]
02 Height (cm) 9 2449 Weighted Mean Difference (Random) 95% CI 0.04 [-0.16, 0.23]
03 Mid-upper arm circumference
(cm)
5 823 Weighted Mean Difference (Random) 95% CI 0.23 [-0.03, 0.48]
04 Triceps skin fold (mm) Weighted Mean Difference (Random) 95% CI Subtotals only
05 Subscapular skin fold (mm) Weighted Mean Difference (Random) 95% CI Subtotals only
06 Haemoglobin (g/dL) 2 538 Weighted Mean Difference (Fixed) 95% CI 0.09 [-0.12, 0.29]





participants Statistical method Effect size
01 Weight (kg) 11 2980 Weighted Mean Difference (Fixed) 95% CI 0.03 [-0.17, 0.23]
02 Height (cm) 8 2222 Weighted Mean Difference (Fixed) 95% CI 0.16 [-0.56, 0.89]
03 Mid-upper arm circumference
(cm)
7 864 Weighted Mean Difference (Fixed) 95% CI 0.08 [-0.11, 0.27]
04 Triceps skin fold (mm) 4 407 Weighted Mean Difference (Random) 95% CI 0.67 [-0.39, 1.72]
05 Subscapular skin fold (mm) Weighted Mean Difference (Random) 95% CI Subtotals only
06 Body mass index Weighted Mean Difference (Fixed) 95% CI Totals not selected
07 Haemoglobin (g/L) 4 646 Weighted Mean Difference (Fixed) 95% CI 1.49 [-0.39, 3.36]
08 Harvard Step Test Weighted Mean Difference (Fixed) 95% CI Subtotals only





participants Statistical method Effect size
01 Weight (kg) 6 1714 Weighted Mean Difference (Random) 95% CI 0.05 [-0.24, 0.33]
02 Height (cm) 6 1715 Weighted Mean Difference (Fixed) 95% CI -0.02 [-0.15, 0.12]
03 Mid-upper arm circumference
(cm)
4 658 Weighted Mean Difference (Random) 95% CI 0.06 [-0.24, 0.36]
04 Triceps skin fold (mm) Weighted Mean Difference (Random) 95% CI Subtotals only
05 Subscapular skin fold (mm) Weighted Mean Difference (Fixed) 95% CI Totals not selected
06 Haemoglobin (g/dL) Weighted Mean Difference (Fixed) 95% CI Subtotals only





participants Statistical method Effect size
01 Weight (kg) 5 2311 Weighted Mean Difference (Fixed) 95% CI -0.07 [-0.29, 0.14]
02 Height (cm) 4 1630 Weighted Mean Difference (Fixed) 95% CI -0.32 [-1.16, 0.51]
03 Mid-upper arm circumference
(cm)
3 581 Weighted Mean Difference (Fixed) 95% CI 0.04 [-0.21, 0.28]
04 Triceps skin fold (mm) Weighted Mean Difference (Fixed) 95% CI Totals not selected
05 Subscapular skin fold (mm) Weighted Mean Difference (Fixed) 95% CI Totals not selected
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participants Statistical method Effect size
01 Weight (kg) 3 1219 Weighted Mean Difference (Random) 95% CI 0.46 [-0.47, 1.39]
02 Height (cm) 3 1219 Weighted Mean Difference (Fixed) 95% CI -0.26 [-0.84, 0.31]





participants Statistical method Effect size
01 Weight (kg) 2 1169 Weighted Mean Difference (Random) 95% CI 0.00 [-0.18, 0.19]
02 Height (cm) 2 1169 Weighted Mean Difference (Fixed) 95% CI -0.08 [-0.89, 0.72]
03 Haemoglobin (g/dL) Weighted Mean Difference (Fixed) 95% CI Totals not selected





participants Statistical method Effect size
01 Single dose: change in weight
(kg)
9 2398 Weighted Mean Difference (Random) 95% CI 0.34 [0.04, 0.64]
02 Single dose: change in height
(cm)
9 2449 Weighted Mean Difference (Random) 95% CI 0.04 [-0.16, 0.23]
03 Multiple dose < 1 year: change
in weight (kg)
6 1714 Weighted Mean Difference (Random) 95% CI 0.05 [-0.24, 0.33]
04 Multiple dose < 1 year: change
in height (cm)
6 1715 Weighted Mean Difference (Fixed) 95% CI -0.02 [-0.15, 0.12]
05 Single dose: end value for
weight (kg)
10 2967 Weighted Mean Difference (Fixed) 95% CI 0.03 [-0.17, 0.23]
06 Single dose: end value for
height (cm)
8 2222 Weighted Mean Difference (Fixed) 95% CI 0.16 [-0.56, 0.89]
07 Multiple dose < 1 year: end
value for weight (kg)
5 2311 Weighted Mean Difference (Fixed) 95% CI -0.07 [-0.29, 0.14]
08 Multiple dose < 1 year: end
value for height (cm)
4 1630 Weighted Mean Difference (Fixed) 95% CI -0.32 [-1.16, 0.51]





participants Statistical method Effect size
01 Single dose: change Weighted Mean Difference (Random) 95% CI Subtotals only
02 Single dose: end value Weighted Mean Difference (Fixed) 95% CI Subtotals only
03 Multiple dose < 1 year: change
in value
Weighted Mean Difference (Fixed) 95% CI Subtotals only
04 Multiple dose < 1 year: end
value
Weighted Mean Difference (Fixed) 95% CI Subtotals only
05 Multiple dose > 1 year: change
in value
Weighted Mean Difference (Random) 95% CI Subtotals only
06 Multiple dose > 1 year: end
value
Weighted Mean Difference (Fixed) 95% CI Totals not selected
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Cochrane Library number CD000371
Editorial group Cochrane Infectious Diseases Group
Editorial group code HM-INFECTN
G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Single dose: change in value, Outcome 01 Weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 01 Single dose: change in value
Outcome: 01 Weight (kg)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 1.00 (0.32) 27 0.30 (0.51) 11.2 0.70 [ 0.47, 0.93 ]
Awasthi 2000 592 0.54 (1.34) 395 0.71 (1.23) 11.6 -0.17 [ -0.33, -0.01 ]
Palupi 1997 95 0.51 (0.73) 96 0.45 (0.58) 11.4 0.06 [ -0.13, 0.25 ]
Stephenson 1989 78 2.10 (0.79) 72 0.80 (0.85) 10.9 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 3.30 (1.76) 93 2.20 (1.16) 9.6 1.10 [ 0.68, 1.52 ]
Watkins 1996 116 0.99 (0.65) 110 0.98 (0.63) 11.5 0.01 [ -0.16, 0.18 ]
Subtotal (95% CI) 1005 793 66.3 0.48 [ 0.04, 0.92 ]
Test for heterogeneity chi-square=129.39 df=5 p=<0.0001 I² =96.1%
Test for overall effect z=2.14 p=0.03
02 Mebendazole
Donnen 1998 112 0.44 (0.72) 110 0.59 (0.74) 11.4 -0.15 [ -0.34, 0.04 ]
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 11.6 0.02 [ -0.13, 0.17 ]
Subtotal (95% CI) 278 291 23.0 -0.05 [ -0.22, 0.11 ]
Test for heterogeneity chi-square=1.85 df=1 p=0.17 I² =45.8%
Test for overall effect z=0.65 p=0.5
03 Pyrantel
Sarkar 2002 40 0.92 (0.84) 41 0.54 (0.45) 10.7 0.38 [ 0.09, 0.67 ]
Subtotal (95% CI) 40 41 10.7 0.38 [ 0.09, 0.67 ]
Test for heterogeneity: not applicable
-4.0 -2.0 0 2.0 4.0
Favours control Favours deworming (Continued . . . )
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(. . . Continued)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Test for overall effect z=2.53 p=0.01
Total (95% CI) 1323 1125 100.0 0.34 [ 0.05, 0.64 ]
Test for heterogeneity chi-square=148.35 df=8 p=<0.0001 I² =94.6%
Test for overall effect z=2.26 p=0.02
-4.0 -2.0 0 2.0 4.0
Favours control Favours deworming
Analysis 01.02. Comparison 01 Single dose: change in value, Outcome 02 Height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 01 Single dose: change in value
Outcome: 02 Height (cm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 0.90 (0.53) 27 0.80 (0.57) 12.5 0.10 [ -0.19, 0.39 ]
Awasthi 2000 592 4.19 (5.08) 395 4.59 (5.25) 5.8 -0.40 [ -1.06, 0.26 ]
Palupi 1997 95 1.20 (0.90) 96 1.40 (1.00) 13.1 -0.20 [ -0.47, 0.07 ]
Stephenson 1989 78 2.80 (0.79) 72 2.20 (0.85) 13.2 0.60 [ 0.34, 0.86 ]
Stephenson 1993 96 3.80 (1.18) 93 3.70 (1.16) 11.5 0.10 [ -0.23, 0.43 ]
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 16.1 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 1005 794 72.1 0.09 [ -0.15, 0.32 ]
Test for heterogeneity chi-square=21.13 df=5 p=0.0008 I² =76.3%
Test for overall effect z=0.74 p=0.5
02 Mebendazole
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 7.5 -0.62 [ -1.15, -0.09 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 12.5 0.08 [ -0.21, 0.37 ]
Subtotal (95% CI) 278 291 20.0 -0.23 [ -0.92, 0.45 ]
Test for heterogeneity chi-square=5.12 df=1 p=0.02 I² =80.5%
Test for overall effect z=0.67 p=0.5
03 Pyrantel
Sarkar 2002 40 1.20 (1.50) 41 1.10 (0.70) 7.9 0.10 [ -0.41, 0.61 ]
Subtotal (95% CI) 40 41 7.9 0.10 [ -0.41, 0.61 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.38 p=0.7
-4.0 -2.0 0 2.0 4.0
Favours control Favours deworming (Continued . . . )
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(. . . Continued)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Total (95% CI) 1323 1126 100.0 0.04 [ -0.16, 0.23 ]
Test for heterogeneity chi-square=27.93 df=8 p=0.0005 I² =71.4%
Test for overall effect z=0.36 p=0.7
-4.0 -2.0 0 2.0 4.0
Favours control Favours deworming
Analysis 01.03. Comparison 01 Single dose: change in value, Outcome 03 Mid-upper arm circumference (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 01 Single dose: change in value
Outcome: 03 Mid-upper arm circumference (cm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 0.60 (0.37) 27 0.30 (0.26) 19.8 0.30 [ 0.13, 0.47 ]
Stephenson 1989 78 0.70 (0.44) 72 0.20 (0.51) 20.2 0.50 [ 0.35, 0.65 ]
Stephenson 1993 96 0.80 (0.49) 93 0.30 (0.39) 20.7 0.50 [ 0.37, 0.63 ]
Watkins 1996 106 0.39 (0.51) 101 0.30 (0.40) 20.7 0.09 [ -0.03, 0.21 ]
Subtotal (95% CI) 308 293 81.3 0.35 [ 0.14, 0.55 ]
Test for heterogeneity chi-square=26.08 df=3 p=<0.0001 I² =88.5%
Test for overall effect z=3.26 p=0.001
02 Mebendazole
Donnen 1998 112 0.11 (0.84) 110 0.41 (0.84) 18.7 -0.30 [ -0.52, -0.08 ]
Subtotal (95% CI) 112 110 18.7 -0.30 [ -0.52, -0.08 ]
Test for heterogeneity: not applicable
Test for overall effect z=2.66 p=0.008
Total (95% CI) 420 403 100.0 0.23 [ -0.03, 0.48 ]
Test for heterogeneity chi-square=55.09 df=4 p=<0.0001 I² =92.7%
Test for overall effect z=1.76 p=0.08
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Analysis 01.04. Comparison 01 Single dose: change in value, Outcome 04 Triceps skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 01 Single dose: change in value
Outcome: 04 Triceps skin fold (mm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 1.00 (0.69) 27 0.20 (0.47) 32.4 0.80 [ 0.49, 1.11 ]
Stephenson 1989 78 1.00 (0.71) 72 -0.20 (0.68) 34.2 1.20 [ 0.98, 1.42 ]
Stephenson 1993 96 2.00 (1.08) 93 0.20 (0.77) 33.4 1.80 [ 1.53, 2.07 ]
Subtotal (95% CI) 202 192 100.0 1.27 [ 0.74, 1.80 ]
Test for heterogeneity chi-square=24.20 df=2 p=<0.0001 I² =91.7%
Test for overall effect z=4.68 p<0.00001
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Analysis 01.05. Comparison 01 Single dose: change in value, Outcome 05 Subscapular skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 01 Single dose: change in value
Outcome: 05 Subscapular skin fold (mm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 0.90 (0.53) 27 0.10 (0.94) 24.3 0.80 [ 0.39, 1.21 ]
Stephenson 1989 78 0.90 (0.62) 72 -0.30 (0.68) 39.0 1.20 [ 0.99, 1.41 ]
Stephenson 1993 96 1.80 (0.88) 93 0.40 (0.77) 36.8 1.40 [ 1.16, 1.64 ]
Subtotal (95% CI) 202 192 100.0 1.18 [ 0.90, 1.46 ]
Test for heterogeneity chi-square=6.40 df=2 p=0.04 I² =68.7%
Test for overall effect z=8.27 p<0.00001
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Analysis 01.06. Comparison 01 Single dose: change in value, Outcome 06 Haemoglobin (g/dL)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 01 Single dose: change in value
Outcome: 06 Haemoglobin (g/dL)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Mebendazole
Garg 2002 166 0.54 (1.42) 181 0.48 (1.47) 45.2 0.06 [ -0.24, 0.36 ]
Subtotal (95% CI) 166 181 45.2 0.06 [ -0.24, 0.36 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.39 p=0.7
02 Albendazole
Palupi 1997 95 0.75 (0.88) 96 0.64 (1.06) 54.8 0.11 [ -0.17, 0.39 ]
Subtotal (95% CI) 95 96 54.8 0.11 [ -0.17, 0.39 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.78 p=0.4
Total (95% CI) 261 277 100.0 0.09 [ -0.12, 0.29 ]
Test for heterogeneity chi-square=0.06 df=1 p=0.81 I² =0.0%
Test for overall effect z=0.84 p=0.4
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Analysis 02.01. Comparison 02 Single dose: end value, Outcome 01 Weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 01 Weight (kg)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 21.10 (2.43) 27 21.60 (3.90) 1.3 -0.50 [ -2.22, 1.22 ]
Awasthi 2000 592 10.70 (2.10) 395 10.80 (1.90) 62.2 -0.10 [ -0.35, 0.15 ]
Stephenson 1989 78 23.40 (3.80) 72 22.50 (4.41) 2.3 0.90 [ -0.42, 2.22 ]
Stephenson 1993 96 31.30 (7.45) 93 31.30 (7.71) 0.8 0.0 [ -2.16, 2.16 ]
Sur 2005 342 12.60 (5.73) 340 12.10 (4.61) 6.5 0.50 [ -0.28, 1.28 ]
Watkins 1996 116 24.36 (3.99) 110 24.93 (4.20) 3.5 -0.57 [ -1.64, 0.50 ]
Subtotal (95% CI) 1252 1037 76.6 -0.05 [ -0.27, 0.18 ]
Test for heterogeneity chi-square=5.21 df=5 p=0.39 I² =4.1%
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(. . . Continued)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Test for overall effect z=0.40 p=0.7
02 Piperazine
Freij 1979i 6 12.30 (2.91) 7 12.10 (2.29) 0.5 0.20 [ -2.68, 3.08 ]
Subtotal (95% CI) 6 7 0.5 0.20 [ -2.68, 3.08 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.14 p=0.9
03 Pyrantel
Hadju 1996 34 20.30 (3.20) 30 19.90 (2.20) 2.2 0.40 [ -0.93, 1.73 ]
Sarkar 2002 40 19.30 (6.60) 41 18.90 (5.20) 0.6 0.40 [ -2.19, 2.99 ]
Subtotal (95% CI) 74 71 2.8 0.40 [ -0.79, 1.59 ]
Test for heterogeneity chi-square=0.0 df=1 p=1.00 I² =0.0%
Test for overall effect z=0.66 p=0.5
04 Mebendazole
Donnen 1998 96 9.82 (2.45) 90 9.48 (2.92) 6.6 0.34 [ -0.44, 1.12 ]
Garg 2002 166 14.35 (2.58) 181 14.11 (2.56) 13.5 0.24 [ -0.30, 0.78 ]
Subtotal (95% CI) 262 271 20.1 0.27 [ -0.17, 0.72 ]
Test for heterogeneity chi-square=0.04 df=1 p=0.84 I² =0.0%
Test for overall effect z=1.20 p=0.2
Total (95% CI) 1594 1386 100.0 0.03 [ -0.17, 0.23 ]
Test for heterogeneity chi-square=7.22 df=10 p=0.70 I² =0.0%
Test for overall effect z=0.31 p=0.8
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Analysis 02.02. Comparison 02 Single dose: end value, Outcome 02 Height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 02 Height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 118.60 (6.83) 27 119.00 (7.33) 3.7 -0.40 [ -4.15, 3.35 ]
Awasthi 2000 592 86.23 (8.37) 395 86.21 (8.31) 46.5 0.02 [ -1.04, 1.08 ]
Stephenson 1989 78 126.40 (7.42) 72 124.50 (8.15) 8.4 1.90 [ -0.60, 4.40 ]
Stephenson 1993 96 138.20 (9.80) 93 139.20 (11.19) 5.8 -1.00 [ -4.00, 2.00 ]
Watkins 1996 116 121.01 (7.75) 111 121.76 (7.90) 12.6 -0.75 [ -2.79, 1.29 ]
Subtotal (95% CI) 910 698 77.0 0.00 [ -0.82, 0.83 ]
Test for heterogeneity chi-square=3.21 df=4 p=0.52 I² =0.0%
Test for overall effect z=0.00 p=1
02 Mebendazole
Donnen 1998 96 77.80 (9.40) 90 76.50 (11.80) 5.5 1.30 [ -1.78, 4.38 ]
Garg 2002 166 95.06 (8.25) 181 94.71 (8.61) 16.6 0.35 [ -1.42, 2.12 ]
Subtotal (95% CI) 262 271 22.2 0.59 [ -0.95, 2.12 ]
Test for heterogeneity chi-square=0.27 df=1 p=0.60 I² =0.0%
Test for overall effect z=0.75 p=0.5
03 Pyrantel
Sarkar 2002 40 115.00 (18.90) 41 111.20 (17.60) 0.8 3.80 [ -4.16, 11.76 ]
Subtotal (95% CI) 40 41 0.8 3.80 [ -4.16, 11.76 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.94 p=0.3
Total (95% CI) 1212 1010 100.0 0.16 [ -0.56, 0.89 ]
Test for heterogeneity chi-square=4.73 df=7 p=0.69 I² =0.0%
Test for overall effect z=0.44 p=0.7
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Analysis 02.03. Comparison 02 Single dose: end value, Outcome 03 Mid-upper arm circumference (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 03 Mid-upper arm circumference (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 15.90 (1.01) 27 16.10 (1.45) 8.4 -0.20 [ -0.86, 0.46 ]
Stephenson 1989 78 16.70 (1.41) 72 16.30 (1.53) 16.6 0.40 [ -0.07, 0.87 ]
Stephenson 1993 96 18.40 (1.96) 93 18.00 (2.12) 10.9 0.40 [ -0.18, 0.98 ]
Watkins 1996 116 18.67 (1.34) 111 18.79 (1.31) 31.2 -0.12 [ -0.46, 0.22 ]
Subtotal (95% CI) 318 303 67.2 0.08 [ -0.15, 0.32 ]
Test for heterogeneity chi-square=4.90 df=3 p=0.18 I² =38.8%
Test for overall effect z=0.69 p=0.5
02 Mebendazole
Donnen 1998 96 13.50 (1.40) 90 13.40 (1.40) 22.9 0.10 [ -0.30, 0.50 ]
Subtotal (95% CI) 96 90 22.9 0.10 [ -0.30, 0.50 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.49 p=0.6
03 Piperazine
Freij 1979i 6 14.50 (1.13) 7 14.80 (1.44) 1.9 -0.30 [ -1.70, 1.10 ]
Freij 1979ii 24 14.60 (1.20) 20 14.50 (1.10) 8.0 0.10 [ -0.58, 0.78 ]
Subtotal (95% CI) 30 27 9.9 0.02 [ -0.59, 0.64 ]
Test for heterogeneity chi-square=0.25 df=1 p=0.61 I² =0.0%
Test for overall effect z=0.08 p=0.9
Total (95% CI) 444 420 100.0 0.08 [ -0.11, 0.27 ]
Test for heterogeneity chi-square=5.20 df=6 p=0.52 I² =0.0%
Test for overall effect z=0.83 p=0.4
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Analysis 02.04. Comparison 02 Single dose: end value, Outcome 04 Triceps skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 04 Triceps skin fold (mm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 7.70 (1.80) 27 6.90 (2.49) 25.0 0.80 [ -0.35, 1.95 ]
Stephenson 1989 78 7.70 (1.94) 72 7.60 (2.04) 31.4 0.10 [ -0.54, 0.74 ]
Stephenson 1993 96 9.10 (2.73) 93 7.30 (2.50) 30.2 1.80 [ 1.05, 2.55 ]
Subtotal (95% CI) 202 192 86.5 0.89 [ -0.24, 2.03 ]
Test for heterogeneity chi-square=11.52 df=2 p=0.003 I² =82.6%
Test for overall effect z=1.55 p=0.1
02 Piperazine
Freij 1979i 6 9.80 (1.51) 7 10.60 (2.59) 13.5 -0.80 [ -3.07, 1.47 ]
Subtotal (95% CI) 6 7 13.5 -0.80 [ -3.07, 1.47 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.69 p=0.5
Total (95% CI) 208 199 100.0 0.67 [ -0.39, 1.72 ]
Test for heterogeneity chi-square=13.40 df=3 p=0.004 I² =77.6%
Test for overall effect z=1.24 p=0.2
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Analysis 02.05. Comparison 02 Single dose: end value, Outcome 05 Subscapular skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 05 Subscapular skin fold (mm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 5.50 (1.01) 27 5.00 (1.61) 29.5 0.50 [ -0.21, 1.21 ]
Stephenson 1989 78 5.70 (1.32) 72 5.40 (1.19) 37.1 0.30 [ -0.10, 0.70 ]
Stephenson 1993 96 6.80 (1.96) 93 5.40 (1.93) 33.4 1.40 [ 0.85, 1.95 ]
Subtotal (95% CI) 202 192 100.0 0.73 [ 0.02, 1.44 ]
Test for heterogeneity chi-square=10.11 df=2 p=0.006 I² =80.2%
Test for overall effect z=2.01 p=0.04
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Analysis 02.06. Comparison 02 Single dose: end value, Outcome 06 Body mass index
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 06 Body mass index
Study Deworming Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
01 Albendazole
Simeon 1995 206 15.60 (1.30) 201 15.80 (1.40) -0.20 [ -0.46, 0.06 ]
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Analysis 02.07. Comparison 02 Single dose: end value, Outcome 07 Haemoglobin (g/L)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 07 Haemoglobin (g/L)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Adams 1994 28 108.00 (12.17) 27 106.00 (12.47) 8.3 2.00 [ -4.51, 8.51 ]
Palupi 1997 95 120.10 (9.70) 96 118.60 (11.40) 39.0 1.50 [ -1.50, 4.50 ]
Stephenson 1993 27 119.00 (10.39) 26 114.00 (10.20) 11.4 5.00 [ -0.54, 10.54 ]
Subtotal (95% CI) 150 149 58.7 2.25 [ -0.19, 4.70 ]
Test for heterogeneity chi-square=1.19 df=2 p=0.55 I² =0.0%
Test for overall effect z=1.80 p=0.07
02 Mebendazole
Garg 2002 166 117.80 (14.17) 181 117.40 (13.45) 41.3 0.40 [ -2.51, 3.31 ]
Subtotal (95% CI) 166 181 41.3 0.40 [ -2.51, 3.31 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.27 p=0.8
Total (95% CI) 316 330 100.0 1.49 [ -0.39, 3.36 ]
Test for heterogeneity chi-square=2.10 df=3 p=0.55 I² =0.0%
Test for overall effect z=1.55 p=0.1
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Analysis 02.08. Comparison 02 Single dose: end value, Outcome 08 Harvard Step Test
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 02 Single dose: end value
Outcome: 08 Harvard Step Test
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Stephenson 1989 18 80.00 (5.51) 15 74.00 (4.65) 23.9 6.00 [ 2.53, 9.47 ]
Stephenson 1993 27 82.00 (3.64) 26 76.00 (3.57) 76.1 6.00 [ 4.06, 7.94 ]
Subtotal (95% CI) 45 41 100.0 6.00 [ 4.31, 7.69 ]
Test for heterogeneity chi-square=0.00 df=1 p=1.00 I² =0.0%
Test for overall effect z=6.94 p<0.00001
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Analysis 03.01. Comparison 03 Multiple dose < 1 year: change in value, Outcome 01 Weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 03 Multiple dose < 1 year: change in value
Outcome: 01 Weight (kg)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 576 0.99 (0.62) 387 0.95 (0.85) 21.0 0.04 [ -0.06, 0.14 ]
Dossa 2001 37 1.20 (1.00) 28 1.20 (1.10) 12.6 0.0 [ -0.52, 0.52 ]
Kruger 1996 37 2.32 (0.64) 37 2.70 (1.22) 14.2 -0.38 [ -0.82, 0.06 ]
Stephenson 1993 95 3.10 (1.36) 93 2.20 (1.16) 16.0 0.90 [ 0.54, 1.26 ]
Watkins 1996 116 1.82 (0.86) 110 1.69 (0.73) 19.3 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 861 655 83.1 0.15 [ -0.15, 0.45 ]
Test for heterogeneity chi-square=24.87 df=4 p=<0.0001 I² =83.9%
Test for overall effect z=0.99 p=0.3
02 Mebendazole
Donnen 1998 100 1.64 (1.12) 98 2.09 (1.19) 16.9 -0.45 [ -0.77, -0.13 ]
Subtotal (95% CI) 100 98 16.9 -0.45 [ -0.77, -0.13 ]
Test for heterogeneity: not applicable
Test for overall effect z=2.74 p=0.006
Total (95% CI) 961 753 100.0 0.05 [ -0.24, 0.33 ]
Test for heterogeneity chi-square=34.80 df=5 p=<0.0001 I² =85.6%
Test for overall effect z=0.33 p=0.7
-4.0 -2.0 0 2.0 4.0
Favours control Favours deworming
66Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 03.02. Comparison 03 Multiple dose < 1 year: change in value, Outcome 02 Height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 03 Multiple dose < 1 year: change in value
Outcome: 02 Height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 576 2.87 (2.18) 387 2.98 (2.20) 22.1 -0.11 [ -0.39, 0.17 ]
Dossa 2001 37 6.50 (2.60) 28 6.00 (2.50) 1.1 0.50 [ -0.75, 1.75 ]
Kruger 1996 37 5.62 (0.90) 37 5.54 (0.91) 10.4 0.08 [ -0.33, 0.49 ]
Stephenson 1993 95 3.60 (1.07) 93 3.70 (1.16) 17.3 -0.10 [ -0.42, 0.22 ]
Watkins 1996 116 2.45 (0.75) 111 2.39 (0.73) 47.6 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 861 656 98.5 0.00 [ -0.13, 0.13 ]
Test for heterogeneity chi-square=2.09 df=4 p=0.72 I² =0.0%
Test for overall effect z=0.01 p=1
02 Mebendazole
Donnen 1998 100 7.27 (3.56) 98 8.46 (4.18) 1.5 -1.19 [ -2.27, -0.11 ]
Subtotal (95% CI) 100 98 1.5 -1.19 [ -2.27, -0.11 ]
Test for heterogeneity: not applicable
Test for overall effect z=2.15 p=0.03
Total (95% CI) 961 754 100.0 -0.02 [ -0.15, 0.12 ]
Test for heterogeneity chi-square=6.67 df=5 p=0.25 I² =25.1%
Test for overall effect z=0.25 p=0.8
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Analysis 03.03. Comparison 03 Multiple dose < 1 year: change in value, Outcome 03 Mid-upper arm
circumference (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 03 Multiple dose < 1 year: change in value
Outcome: 03 Mid-upper arm circumference (cm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Dossa 2001 37 0.10 (0.80) 28 0.10 (0.90) 19.0 0.0 [ -0.42, 0.42 ]
Stephenson 1993 95 0.70 (0.49) 93 0.30 (0.39) 29.0 0.40 [ 0.27, 0.53 ]
Watkins 1996 106 0.60 (0.51) 101 0.52 (0.50) 28.7 0.08 [ -0.06, 0.22 ]
Subtotal (95% CI) 238 222 76.7 0.19 [ -0.08, 0.46 ]
Test for heterogeneity chi-square=12.59 df=2 p=0.002 I² =84.1%
Test for overall effect z=1.40 p=0.2
02 Mebendazole
Donnen 1998 100 0.62 (1.00) 98 0.97 (1.16) 23.3 -0.35 [ -0.65, -0.05 ]
Subtotal (95% CI) 100 98 23.3 -0.35 [ -0.65, -0.05 ]
Test for heterogeneity: not applicable
Test for overall effect z=2.27 p=0.02
Total (95% CI) 338 320 100.0 0.06 [ -0.24, 0.36 ]
Test for heterogeneity chi-square=26.11 df=3 p=<0.0001 I² =88.5%
Test for overall effect z=0.38 p=0.7
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Analysis 03.04. Comparison 03 Multiple dose < 1 year: change in value, Outcome 04 Triceps skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 03 Multiple dose < 1 year: change in value
Outcome: 04 Triceps skin fold (mm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Dossa 2001 38 -0.60 (1.30) 28 0.20 (1.70) 49.1 -0.80 [ -1.55, -0.05 ]
Stephenson 1993 95 2.00 (1.17) 93 0.20 (0.77) 50.9 1.80 [ 1.52, 2.08 ]
Subtotal (95% CI) 133 121 100.0 0.52 [ -2.02, 3.07 ]
Test for heterogeneity chi-square=40.13 df=1 p=<0.0001 I² =97.5%
Test for overall effect z=0.40 p=0.7
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Analysis 03.05. Comparison 03 Multiple dose < 1 year: change in value, Outcome 05 Subscapular skin fold
(mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 03 Multiple dose < 1 year: change in value
Outcome: 05 Subscapular skin fold (mm)
Study Deworming Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
01 Albendazole
Stephenson 1993 95 1.90 (1.07) 93 0.40 (0.77) 1.50 [ 1.23, 1.77 ]
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Analysis 03.06. Comparison 03 Multiple dose < 1 year: change in value, Outcome 06 Haemoglobin (g/dL)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 03 Multiple dose < 1 year: change in value
Outcome: 06 Haemoglobin (g/dL)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Dossa 2001 38 0.20 (1.60) 32 0.40 (1.00) 19.4 -0.20 [ -0.82, 0.42 ]
Kruger 1996 37 0.24 (0.60) 37 0.26 (0.72) 80.6 -0.02 [ -0.32, 0.28 ]
Subtotal (95% CI) 75 69 100.0 -0.05 [ -0.33, 0.22 ]
Test for heterogeneity chi-square=0.26 df=1 p=0.61 I² =0.0%
Test for overall effect z=0.40 p=0.7
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Analysis 04.01. Comparison 04 Multiple dose < 1 year: end value, Outcome 01 Weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 04 Multiple dose < 1 year: end value
Outcome: 01 Weight (kg)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 619 11.67 (1.97) 410 11.78 (1.86) 81.2 -0.11 [ -0.35, 0.13 ]
Stephenson 1993 95 31.90 (7.99) 93 31.30 (7.17) 1.0 0.60 [ -1.57, 2.77 ]
Sur 2005 342 12.90 (7.40) 340 12.40 (4.61) 5.4 0.50 [ -0.42, 1.42 ]
Watkins 1996 116 25.19 (4.20) 110 25.63 (4.30) 3.7 -0.44 [ -1.55, 0.67 ]
Subtotal (95% CI) 1172 953 91.3 -0.08 [ -0.30, 0.14 ]
Test for heterogeneity chi-square=2.35 df=3 p=0.50 I² =0.0%
Test for overall effect z=0.70 p=0.5
02 Mebendazole
Donnen 1998 96 10.99 (2.32) 90 10.98 (2.69) 8.7 0.01 [ -0.71, 0.73 ]
Subtotal (95% CI) 96 90 8.7 0.01 [ -0.71, 0.73 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.03 p=1
Total (95% CI) 1268 1043 100.0 -0.07 [ -0.29, 0.14 ]
Test for heterogeneity chi-square=2.41 df=4 p=0.66 I² =0.0%
Test for overall effect z=0.66 p=0.5
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Analysis 04.02. Comparison 04 Multiple dose < 1 year: end value, Outcome 02 Height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 04 Multiple dose < 1 year: end value
Outcome: 02 Height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 619 88.99 (8.19) 410 89.32 (8.12) 67.1 -0.33 [ -1.35, 0.69 ]
Stephenson 1993 95 138.40 (11.11) 93 139.20 (11.19) 6.8 -0.80 [ -3.99, 2.39 ]
Watkins 1996 116 122.03 (7.75) 111 122.78 (8.00) 16.5 -0.75 [ -2.80, 1.30 ]
Subtotal (95% CI) 830 614 90.4 -0.44 [ -1.32, 0.43 ]
Test for heterogeneity chi-square=0.18 df=2 p=0.91 I² =0.0%
Test for overall effect z=0.99 p=0.3
02 Mebendazole
Donnen 1998 96 83.20 (8.60) 90 82.40 (10.00) 9.6 0.80 [ -1.89, 3.49 ]
Subtotal (95% CI) 96 90 9.6 0.80 [ -1.89, 3.49 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.58 p=0.6
Total (95% CI) 926 704 100.0 -0.32 [ -1.16, 0.51 ]
Test for heterogeneity chi-square=0.92 df=3 p=0.82 I² =0.0%
Test for overall effect z=0.76 p=0.4
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Analysis 04.03. Comparison 04 Multiple dose < 1 year: end value, Outcome 03 Mid-upper arm circumference
(cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 04 Multiple dose < 1 year: end value
Outcome: 03 Mid-upper arm circumference (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Stephenson 1993 95 18.60 (2.34) 93 18.00 (2.12) 14.7 0.60 [ -0.04, 1.24 ]
Watkins 1996 106 18.88 (1.44) 101 19.00 (1.31) 42.6 -0.12 [ -0.49, 0.25 ]
Subtotal (95% CI) 201 194 57.2 0.06 [ -0.26, 0.39 ]
Test for heterogeneity chi-square=3.64 df=1 p=0.06 I² =72.5%
Test for overall effect z=0.39 p=0.7
02 Mebendazole
Donnen 1998 96 14.00 (1.30) 90 14.00 (1.30) 42.8 0.0 [ -0.37, 0.37 ]
Subtotal (95% CI) 96 90 42.8 0.0 [ -0.37, 0.37 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.0 p=1
Total (95% CI) 297 284 100.0 0.04 [ -0.21, 0.28 ]
Test for heterogeneity chi-square=3.70 df=2 p=0.16 I² =46.0%
Test for overall effect z=0.30 p=0.8
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Analysis 04.04. Comparison 04 Multiple dose < 1 year: end value, Outcome 04 Triceps skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 04 Multiple dose < 1 year: end value
Outcome: 04 Triceps skin fold (mm)
Study Deworming Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
01 Albendazole
Stephenson 1993 95 9.20 (3.51) 93 7.30 (2.50) 1.90 [ 1.03, 2.77 ]
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Analysis 04.05. Comparison 04 Multiple dose < 1 year: end value, Outcome 05 Subscapular skin fold (mm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 04 Multiple dose < 1 year: end value
Outcome: 05 Subscapular skin fold (mm)
Study Deworming Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
01 Albendazole
Stephenson 1993 95 7.10 (2.34) 93 5.40 (1.93) 1.70 [ 1.09, 2.31 ]
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Analysis 05.01. Comparison 05 Multiple dose > 1 year: change in value, Outcome 01 Weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 05 Multiple dose > 1 year: change in value
Outcome: 01 Weight (kg)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 601 2.63 (1.34) 444 2.68 (1.20) 35.2 -0.05 [ -0.20, 0.10 ]
Subtotal (95% CI) 601 444 35.2 -0.05 [ -0.20, 0.10 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.63 p=0.5
02 Cluster-randomized trials (albendazole)
Awasthi 1995 25 4.60 (0.55) 25 3.36 (0.60) 34.1 1.24 [ 0.92, 1.56 ]
Awasthi 2001 63 3.22 (2.03) 61 3.05 (1.47) 30.7 0.17 [ -0.45, 0.79 ]
Subtotal (95% CI) 88 86 64.8 0.74 [ -0.31, 1.79 ]
Test for heterogeneity chi-square=8.99 df=1 p=0.003 I² =88.9%
Test for overall effect z=1.39 p=0.2
Total (95% CI) 689 530 100.0 0.46 [ -0.47, 1.39 ]
Test for heterogeneity chi-square=50.85 df=2 p=<0.0001 I² =96.1%
Test for overall effect z=0.96 p=0.3
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Analysis 05.02. Comparison 05 Multiple dose > 1 year: change in value, Outcome 02 Height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 05 Multiple dose > 1 year: change in value
Outcome: 02 Height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 601 9.94 (4.90) 444 10.35 (5.10) 87.7 -0.41 [ -1.03, 0.21 ]
Subtotal (95% CI) 601 444 87.7 -0.41 [ -1.03, 0.21 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.31 p=0.2
02 Cluster-randomized trials (albendazole)
Awasthi 1995 25 17.59 (4.50) 25 16.40 (4.00) 6.0 1.19 [ -1.17, 3.55 ]
Awasthi 2001 63 16.50 (6.51) 61 16.10 (6.48) 6.3 0.40 [ -1.89, 2.69 ]
Subtotal (95% CI) 88 86 12.3 0.78 [ -0.86, 2.42 ]
Test for heterogeneity chi-square=0.22 df=1 p=0.64 I² =0.0%
Test for overall effect z=0.93 p=0.4
Total (95% CI) 689 530 100.0 -0.26 [ -0.84, 0.31 ]
Test for heterogeneity chi-square=2.00 df=2 p=0.37 I² =0.0%
Test for overall effect z=0.90 p=0.4
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Analysis 06.01. Comparison 06 Multiple dose > 1 year: end value, Outcome 01 Weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 06 Multiple dose > 1 year: end value
Outcome: 01 Weight (kg)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 601 12.71 (1.93) 444 12.84 (1.94) 32.7 -0.13 [ -0.37, 0.11 ]
Subtotal (95% CI) 601 444 32.7 -0.13 [ -0.37, 0.11 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.07 p=0.3
02 Cluster-randomized trials (albendazole)
Awasthi 2001 63 9.94 (0.16) 61 9.87 (0.16) 67.3 0.07 [ 0.01, 0.13 ]
Subtotal (95% CI) 63 61 67.3 0.07 [ 0.01, 0.13 ]
Test for heterogeneity: not applicable
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(. . . Continued)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Test for overall effect z=2.44 p=0.01
Total (95% CI) 664 505 100.0 0.00 [ -0.18, 0.19 ]
Test for heterogeneity chi-square=2.58 df=1 p=0.11 I² =61.2%
Test for overall effect z=0.05 p=1
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Analysis 06.02. Comparison 06 Multiple dose > 1 year: end value, Outcome 02 Height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 06 Multiple dose > 1 year: end value
Outcome: 02 Height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Albendazole
Awasthi 2000 601 92.01 (8.02) 444 92.21 (8.08) 66.3 -0.20 [ -1.19, 0.79 ]
Subtotal (95% CI) 601 444 66.3 -0.20 [ -1.19, 0.79 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.40 p=0.7
02 Cluster-randomized trials (albendazole)
Awasthi 2001 63 81.75 (3.96) 61 81.60 (3.91) 33.7 0.15 [ -1.24, 1.54 ]
Subtotal (95% CI) 63 61 33.7 0.15 [ -1.24, 1.54 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.21 p=0.8
Total (95% CI) 664 505 100.0 -0.08 [ -0.89, 0.72 ]
Test for heterogeneity chi-square=0.16 df=1 p=0.69 I² =0.0%
Test for overall effect z=0.20 p=0.8
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Analysis 06.03. Comparison 06 Multiple dose > 1 year: end value, Outcome 03 Haemoglobin (g/dL)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 06 Multiple dose > 1 year: end value
Outcome: 03 Haemoglobin (g/dL)
Study Deworming Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
01 Albendazole
Awasthi 2000 601 96.60 (6.60) 444 96.80 (6.60) -0.20 [ -1.01, 0.61 ]
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Analysis 07.01. Comparison 07 Analysis by worm prevalence or intensity, Outcome 01 Single dose: change in
weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 01 Single dose: change in weight (kg)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 High prevalence/intensity
Adams 1994 28 1.00 (0.32) 27 0.30 (0.51) 11.2 0.70 [ 0.47, 0.93 ]
Donnen 1998 112 0.44 (0.72) 110 0.59 (0.74) 11.4 -0.15 [ -0.34, 0.04 ]
Sarkar 2002 40 0.92 (0.84) 41 0.54 (0.45) 10.7 0.38 [ 0.09, 0.67 ]
Stephenson 1989 78 2.10 (0.79) 72 0.80 (0.85) 11.0 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 3.30 (1.76) 93 2.20 (1.16) 9.7 1.10 [ 0.68, 1.52 ]
Watkins 1996 116 0.99 (0.65) 110 0.98 (0.63) 11.5 0.01 [ -0.16, 0.18 ]
Subtotal (95% CI) 470 453 65.5 0.54 [ 0.08, 1.01 ]
Test for heterogeneity chi-square=113.28 df=5 p=<0.0001 I² =95.6%
Test for overall effect z=2.31 p=0.02
02 Moderate prevalence/low intensity
Palupi 1997 95 0.51 (0.73) 96 0.45 (0.58) 11.4 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 95 96 11.4 0.06 [ -0.13, 0.25 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.63 p=0.5
03 Low prevalence/intensity
Awasthi 2000 592 0.54 (1.34) 395 0.71 (1.23) 11.6 -0.17 [ -0.33, -0.01 ]
Garg 2002 116 1.21 (0.77) 181 1.19 (0.67) 11.5 0.02 [ -0.15, 0.19 ]
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(. . . Continued)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Subtotal (95% CI) 708 576 23.1 -0.08 [ -0.26, 0.11 ]
Test for heterogeneity chi-square=2.50 df=1 p=0.11 I² =60.0%
Test for overall effect z=0.81 p=0.4
Total (95% CI) 1273 1125 100.0 0.34 [ 0.04, 0.64 ]
Test for heterogeneity chi-square=147.69 df=8 p=<0.0001 I² =94.6%
Test for overall effect z=2.23 p=0.03
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Analysis 07.02. Comparison 07 Analysis by worm prevalence or intensity, Outcome 02 Single dose: change in
height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 02 Single dose: change in height (cm)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 High prevalence/intensity
Adams 1994 28 0.90 (0.53) 27 0.80 (0.57) 12.5 0.10 [ -0.19, 0.39 ]
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 7.5 -0.62 [ -1.15, -0.09 ]
Sarkar 2002 40 1.20 (1.50) 41 1.10 (0.70) 7.9 0.10 [ -0.41, 0.61 ]
Stephenson 1989 78 2.80 (0.79) 72 2.20 (0.85) 13.2 0.60 [ 0.34, 0.86 ]
Stephenson 1993 96 3.80 (1.18) 93 3.70 (1.16) 11.5 0.10 [ -0.23, 0.43 ]
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 16.1 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 470 454 68.7 0.10 [ -0.15, 0.35 ]
Test for heterogeneity chi-square=20.95 df=5 p=0.0008 I² =76.1%
Test for overall effect z=0.80 p=0.4
02 Moderate prevalence and low intensity
Palupi 1997 95 1.20 (0.90) 96 1.40 (1.00) 13.1 -0.20 [ -0.47, 0.07 ]
Subtotal (95% CI) 95 96 13.1 -0.20 [ -0.47, 0.07 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.45 p=0.1
03 Low prevalence/intensity
Awasthi 2000 592 4.19 (5.08) 395 4.59 (5.25) 5.8 -0.40 [ -1.06, 0.26 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 12.5 0.08 [ -0.21, 0.37 ]
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(. . . Continued)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Subtotal (95% CI) 758 576 18.3 -0.07 [ -0.50, 0.37 ]
Test for heterogeneity chi-square=1.70 df=1 p=0.19 I² =41.2%
Test for overall effect z=0.30 p=0.8
Total (95% CI) 1323 1126 100.0 0.04 [ -0.16, 0.23 ]
Test for heterogeneity chi-square=27.93 df=8 p=0.0005 I² =71.4%
Test for overall effect z=0.36 p=0.7
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Analysis 07.03. Comparison 07 Analysis by worm prevalence or intensity, Outcome 03 Multiple dose < 1 year:
change in weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 03 Multiple dose < 1 year: change in weight (kg)
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 High prevalence/intensity
Donnen 1998 100 1.64 (1.12) 98 2.09 (1.19) 16.9 -0.45 [ -0.77, -0.13 ]
Stephenson 1993 95 3.10 (1.36) 93 2.20 (1.16) 16.0 0.90 [ 0.54, 1.26 ]
Watkins 1996 116 1.82 (0.86) 110 1.69 (0.73) 19.3 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 311 301 52.3 0.19 [ -0.47, 0.84 ]
Test for heterogeneity chi-square=29.92 df=2 p=<0.0001 I² =93.3%
Test for overall effect z=0.56 p=0.6
02 Moderate prevalence/intensity
Dossa 2001 37 1.20 (1.00) 28 1.20 (1.10) 12.6 0.0 [ -0.52, 0.52 ]
Subtotal (95% CI) 37 28 12.6 0.0 [ -0.52, 0.52 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.0 p=1
03 Low prevalence/intensity
Awasthi 2000 576 0.99 (0.62) 387 0.95 (0.85) 21.0 0.04 [ -0.06, 0.14 ]
Kruger 1996 37 2.32 (0.64) 37 2.70 (1.22) 14.2 -0.38 [ -0.82, 0.06 ]
Subtotal (95% CI) 613 424 35.1 -0.11 [ -0.51, 0.28 ]
Test for heterogeneity chi-square=3.28 df=1 p=0.07 I² =69.5%
Test for overall effect z=0.55 p=0.6
Total (95% CI) 961 753 100.0 0.05 [ -0.24, 0.33 ]
Test for heterogeneity chi-square=34.80 df=5 p=<0.0001 I² =85.6%
Test for overall effect z=0.33 p=0.7
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Analysis 07.04. Comparison 07 Analysis by worm prevalence or intensity, Outcome 04 Multiple dose < 1 year:
change in height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 04 Multiple dose < 1 year: change in height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 HIgh prevalence/intensity
Donnen 1998 100 7.27 (3.56) 98 8.46 (4.18) 1.5 -1.19 [ -2.27, -0.11 ]
Stephenson 1993 95 3.60 (1.07) 93 3.70 (1.16) 17.3 -0.10 [ -0.42, 0.22 ]
Watkins 1996 116 2.45 (0.75) 111 2.39 (0.73) 47.6 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 311 302 66.4 -0.01 [ -0.17, 0.15 ]
Test for heterogeneity chi-square=5.38 df=2 p=0.07 I² =62.8%
Test for overall effect z=0.12 p=0.9
02 Moderate prevalence/intensity
Dossa 2001 37 6.50 (2.60) 28 6.00 (2.50) 1.1 0.50 [ -0.75, 1.75 ]
Subtotal (95% CI) 37 28 1.1 0.50 [ -0.75, 1.75 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.78 p=0.4
03 Low prevalence/intensity
Awasthi 2000 576 2.87 (2.18) 387 2.98 (2.20) 22.1 -0.11 [ -0.39, 0.17 ]
Kruger 1996 37 5.62 (0.90) 37 5.54 (0.91) 10.4 0.08 [ -0.33, 0.49 ]
Subtotal (95% CI) 613 424 32.5 -0.05 [ -0.28, 0.18 ]
Test for heterogeneity chi-square=0.56 df=1 p=0.46 I² =0.0%
Test for overall effect z=0.42 p=0.7
Total (95% CI) 961 754 100.0 -0.02 [ -0.15, 0.12 ]
Test for heterogeneity chi-square=6.67 df=5 p=0.25 I² =25.1%
Test for overall effect z=0.25 p=0.8
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Analysis 07.05. Comparison 07 Analysis by worm prevalence or intensity, Outcome 05 Single dose: end value
for weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 05 Single dose: end value for weight (kg)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 High prevalence/intensity
Adams 1994 28 21.10 (2.43) 27 21.60 (3.90) 1.3 -0.50 [ -2.22, 1.22 ]
Donnen 1998 96 9.82 (2.45) 90 9.48 (2.92) 6.6 0.34 [ -0.44, 1.12 ]
Hadju 1996 34 20.30 (3.20) 30 19.90 (2.20) 2.2 0.40 [ -0.93, 1.73 ]
Sarkar 2002 40 19.30 (6.60) 41 18.90 (5.20) 0.6 0.40 [ -2.19, 2.99 ]
Stephenson 1989 78 23.40 (3.80) 72 22.50 (4.41) 2.3 0.90 [ -0.42, 2.22 ]
Stephenson 1993 96 31.30 (7.45) 93 31.30 (7.71) 0.9 0.0 [ -2.16, 2.16 ]
Watkins 1996 116 24.36 (3.99) 110 24.93 (4.20) 3.5 -0.57 [ -1.64, 0.50 ]
Subtotal (95% CI) 488 463 17.4 0.16 [ -0.32, 0.64 ]
Test for heterogeneity chi-square=3.94 df=6 p=0.68 I² =0.0%
Test for overall effect z=0.65 p=0.5
02 Moderate prevalence/intensity
Sur 2005 342 12.60 (5.73) 340 12.10 (4.61) 6.5 0.50 [ -0.28, 1.28 ]
Subtotal (95% CI) 342 340 6.5 0.50 [ -0.28, 1.28 ]
Test for heterogeneity: not applicable
Test for overall effect z=1.26 p=0.2
03 Low prevalence/intensity
Awasthi 2000 592 10.70 (2.10) 395 10.80 (1.90) 62.5 -0.10 [ -0.35, 0.15 ]
Garg 2002 166 14.35 (2.58) 181 14.11 (2.56) 13.6 0.24 [ -0.30, 0.78 ]
Subtotal (95% CI) 758 576 76.1 -0.04 [ -0.27, 0.19 ]
Test for heterogeneity chi-square=1.24 df=1 p=0.26 I² =19.6%
Test for overall effect z=0.34 p=0.7
Total (95% CI) 1588 1379 100.0 0.03 [ -0.17, 0.23 ]
Test for heterogeneity chi-square=7.21 df=9 p=0.62 I² =0.0%
Test for overall effect z=0.30 p=0.8
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Analysis 07.06. Comparison 07 Analysis by worm prevalence or intensity, Outcome 06 Single dose: end value
for height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 06 Single dose: end value for height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 High prevalence/intensity
Adams 1994 28 118.60 (6.83) 27 119.00 (7.33) 3.7 -0.40 [ -4.15, 3.35 ]
Donnen 1998 96 77.80 (9.40) 90 76.50 (11.80) 5.5 1.30 [ -1.78, 4.38 ]
Sarkar 2002 40 115.00 (18.90) 41 111.20 (17.60) 0.8 3.80 [ -4.16, 11.76 ]
Stephenson 1989 78 126.40 (7.42) 72 124.50 (8.15) 8.4 1.90 [ -0.60, 4.40 ]
Stephenson 1993 96 138.20 (9.80) 93 139.20 (11.19) 5.8 -1.00 [ -4.00, 2.00 ]
Watkins 1996 116 121.01 (7.75) 111 121.76 (7.90) 12.6 -0.75 [ -2.79, 1.29 ]
Subtotal (95% CI) 454 434 36.9 0.26 [ -0.93, 1.45 ]
Test for heterogeneity chi-square=4.59 df=5 p=0.47 I² =0.0%
Test for overall effect z=0.42 p=0.7
02 Low prevalence/intensity
Awasthi 2000 592 86.23 (8.37) 395 86.21 (8.31) 46.5 0.02 [ -1.04, 1.08 ]
Garg 2002 166 95.06 (8.25) 181 94.71 (8.61) 16.6 0.35 [ -1.42, 2.12 ]
Subtotal (95% CI) 758 576 63.1 0.11 [ -0.80, 1.02 ]
Test for heterogeneity chi-square=0.10 df=1 p=0.75 I² =0.0%
Test for overall effect z=0.23 p=0.8
Total (95% CI) 1212 1010 100.0 0.16 [ -0.56, 0.89 ]
Test for heterogeneity chi-square=4.73 df=7 p=0.69 I² =0.0%
Test for overall effect z=0.44 p=0.7
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Analysis 07.07. Comparison 07 Analysis by worm prevalence or intensity, Outcome 07 Multiple dose < 1 year:
end value for weight (kg)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 07 Multiple dose < 1 year: end value for weight (kg)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 High prevalence/intensity
Stephenson 1993 95 31.90 (7.99) 93 31.30 (7.17) 1.0 0.60 [ -1.57, 2.77 ]
Watkins 1996 116 25.19 (4.20) 110 25.63 (4.30) 3.7 -0.44 [ -1.55, 0.67 ]
Subtotal (95% CI) 211 203 4.7 -0.22 [ -1.21, 0.76 ]
Test for heterogeneity chi-square=0.70 df=1 p=0.40 I² =0.0%
Test for overall effect z=0.45 p=0.7
02 Moderate prevalence/intensity
Donnen 1998 96 10.99 (2.32) 90 10.98 (2.69) 8.7 0.01 [ -0.71, 0.73 ]
Sur 2005 342 12.90 (7.40) 340 12.40 (4.61) 5.4 0.50 [ -0.42, 1.42 ]
Subtotal (95% CI) 438 430 14.1 0.20 [ -0.37, 0.77 ]
Test for heterogeneity chi-square=0.67 df=1 p=0.41 I² =0.0%
Test for overall effect z=0.67 p=0.5
03 Low prevalence/intensity
Awasthi 2000 619 11.67 (1.97) 410 11.78 (1.86) 81.2 -0.11 [ -0.35, 0.13 ]
Subtotal (95% CI) 619 410 81.2 -0.11 [ -0.35, 0.13 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.91 p=0.4
Total (95% CI) 1268 1043 100.0 -0.07 [ -0.29, 0.14 ]
Test for heterogeneity chi-square=2.41 df=4 p=0.66 I² =0.0%
Test for overall effect z=0.66 p=0.5
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Analysis 07.08. Comparison 07 Analysis by worm prevalence or intensity, Outcome 08 Multiple dose < 1 year:
end value for height (cm)
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 07 Analysis by worm prevalence or intensity
Outcome: 08 Multiple dose < 1 year: end value for height (cm)
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 HIgh prevalence/intensity
Donnen 1998 96 83.20 (8.60) 90 82.40 (10.00) 9.6 0.80 [ -1.89, 3.49 ]
Stephenson 1993 95 138.40 (11.11) 93 139.20 (11.19) 6.8 -0.80 [ -3.99, 2.39 ]
Watkins 1996 116 122.03 (7.75) 111 122.78 (8.00) 16.5 -0.75 [ -2.80, 1.30 ]
Subtotal (95% CI) 307 294 32.9 -0.31 [ -1.76, 1.14 ]
Test for heterogeneity chi-square=0.92 df=2 p=0.63 I² =0.0%
Test for overall effect z=0.42 p=0.7
02 Low prevalence/intensity
Awasthi 2000 619 88.99 (8.19) 410 89.32 (8.12) 67.1 -0.33 [ -1.35, 0.69 ]
Subtotal (95% CI) 619 410 67.1 -0.33 [ -1.35, 0.69 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.64 p=0.5
Total (95% CI) 926 704 100.0 -0.32 [ -1.16, 0.51 ]
Test for heterogeneity chi-square=0.92 df=3 p=0.82 I² =0.0%
Test for overall effect z=0.76 p=0.4
-10.0 -5.0 0 5.0 10.0
Favours control Favours deworming
83Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 08.01. Comparison 08 Subgroup and sensitivity analyses, Outcome 01 Single dose: change
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 08 Subgroup and sensitivity analyses
Outcome: 01 Single dose: change
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Weight (kg): trials that did not screen for infection
Awasthi 2000 592 0.54 (1.34) 395 0.71 (1.23) 14.8 -0.17 [ -0.33, -0.01 ]
Donnen 1998 112 0.44 (0.72) 110 0.59 (0.74) 14.6 -0.15 [ -0.34, 0.04 ]
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 14.9 0.02 [ -0.13, 0.17 ]
Palupi 1997 95 0.51 (0.73) 96 0.45 (0.58) 14.6 0.06 [ -0.13, 0.25 ]
Stephenson 1989 78 2.10 (0.79) 72 0.80 (0.85) 14.0 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 3.30 (1.76) 93 2.20 (1.16) 12.3 1.10 [ 0.68, 1.52 ]
Watkins 1996 116 0.99 (0.65) 110 0.98 (0.63) 14.8 0.01 [ -0.16, 0.18 ]
Subtotal (95% CI) 1255 1057 100.0 0.28 [ -0.05, 0.62 ]
Test for heterogeneity chi-square=120.64 df=6 p=<0.0001 I² =95.0%
Test for overall effect z=1.67 p=0.09
02 Weight (kg): trials with adequate or unclear allocation concealment
Adams 1994 28 1.00 (0.32) 27 0.30 (0.51) 12.7 0.70 [ 0.47, 0.93 ]
Donnen 1998 112 0.44 (0.72) 110 0.59 (0.74) 12.9 -0.15 [ -0.34, 0.04 ]
Garg 2002 166 1.21 (0.77) 181 1.19 (0.67) 13.1 0.02 [ -0.13, 0.17 ]
Palupi 1997 95 0.51 (0.73) 96 0.45 (0.58) 12.9 0.06 [ -0.13, 0.25 ]
Sarkar 2002 40 0.92 (0.84) 41 0.54 (0.45) 12.1 0.38 [ 0.09, 0.67 ]
Stephenson 1989 78 2.10 (0.79) 72 0.80 (0.85) 12.4 1.30 [ 1.04, 1.56 ]
Stephenson 1993 96 3.30 (1.76) 93 2.20 (1.16) 11.0 1.10 [ 0.68, 1.52 ]
Watkins 1996 116 0.99 (0.65) 110 0.98 (0.63) 13.0 0.01 [ -0.16, 0.18 ]
Subtotal (95% CI) 731 730 100.0 0.41 [ 0.08, 0.73 ]
Test for heterogeneity chi-square=129.44 df=7 p=<0.0001 I² =94.6%
Test for overall effect z=2.47 p=0.01
03 Height (cm): trials that did not screen for infection
Awasthi 2000 592 4.19 (5.08) 395 4.59 (5.25) 8.1 -0.40 [ -1.06, 0.26 ]
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 10.2 -0.62 [ -1.15, -0.09 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 15.6 0.08 [ -0.21, 0.37 ]
Palupi 1997 95 1.20 (0.90) 96 1.40 (1.00) 16.2 -0.20 [ -0.47, 0.07 ]
Stephenson 1989 78 2.80 (0.79) 72 2.20 (0.85) 16.3 0.60 [ 0.34, 0.86 ]
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Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Stephenson 1993 96 3.80 (1.18) 93 3.70 (1.16) 14.6 0.10 [ -0.23, 0.43 ]
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 18.9 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 1255 1058 100.0 0.01 [ -0.23, 0.25 ]
Test for heterogeneity chi-square=27.90 df=6 p=<0.0001 I² =78.5%
Test for overall effect z=0.07 p=0.9
04 Height (cm): trials with adequate or unclear allocation concealment
Adams 1994 28 0.90 (0.53) 27 0.80 (0.57) 13.3 0.10 [ -0.19, 0.39 ]
Donnen 1998 112 1.96 (1.99) 110 2.58 (2.05) 7.9 -0.62 [ -1.15, -0.09 ]
Garg 2002 166 4.25 (1.42) 181 4.17 (1.35) 13.3 0.08 [ -0.21, 0.37 ]
Palupi 1997 95 1.20 (0.90) 96 1.40 (1.00) 13.9 -0.20 [ -0.47, 0.07 ]
Sarkar 2002 40 1.20 (1.50) 41 1.10 (0.70) 8.3 0.10 [ -0.41, 0.61 ]
Stephenson 1989 78 2.80 (0.79) 72 2.20 (0.85) 14.0 0.60 [ 0.34, 0.86 ]
Stephenson 1993 96 3.80 (1.18) 93 3.70 (1.16) 12.2 0.10 [ -0.23, 0.43 ]
Watkins 1996 116 1.44 (0.54) 111 1.38 (0.53) 17.1 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 731 731 100.0 0.06 [ -0.14, 0.26 ]
Test for heterogeneity chi-square=25.90 df=7 p=0.0005 I² =73.0%
Test for overall effect z=0.62 p=0.5
05 Mid-upper arm circumference (cm): trials that did not screen for infection
Donnen 1998 112 0.11 (0.84) 110 0.41 (0.84) 23.6 -0.30 [ -0.52, -0.08 ]
Stephenson 1989 78 0.70 (0.44) 72 0.20 (0.51) 25.1 0.50 [ 0.35, 0.65 ]
Stephenson 1993 96 0.80 (0.49) 93 0.30 (0.39) 25.6 0.50 [ 0.37, 0.63 ]
Watkins 1996 106 0.39 (0.51) 101 0.30 (0.40) 25.6 0.09 [ -0.03, 0.21 ]
Subtotal (95% CI) 392 376 100.0 0.21 [ -0.11, 0.52 ]
Test for heterogeneity chi-square=55.02 df=3 p=<0.0001 I² =94.5%
Test for overall effect z=1.26 p=0.2
06 Triceps skin fold (mm): trials that did not screen for infection
Stephenson 1989 78 1.00 (0.71) 72 -0.20 (0.68) 50.8 1.20 [ 0.98, 1.42 ]
Stephenson 1993 96 2.00 (1.08) 93 0.20 (0.77) 49.2 1.80 [ 1.53, 2.07 ]
Subtotal (95% CI) 174 165 100.0 1.50 [ 0.91, 2.08 ]
Test for heterogeneity chi-square=11.46 df=1 p=0.0007 I² =91.3%
Test for overall effect z=4.98 p<0.00001
07 Subscapular skin fold (mm): trials that did not screen children for infection
Stephenson 1989 78 0.90 (0.62) 72 -0.30 (0.68) 53.9 1.20 [ 0.99, 1.41 ]
Stephenson 1993 96 1.80 (0.88) 93 0.40 (0.77) 46.1 1.40 [ 1.16, 1.64 ]
Subtotal (95% CI) 174 165 100.0 1.29 [ 1.10, 1.49 ]
Test for heterogeneity chi-square=1.55 df=1 p=0.21 I² =35.5%
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Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Test for overall effect z=12.96 p<0.00001
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Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 08 Subgroup and sensitivity analyses
Outcome: 02 Single dose: end value
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Mean weight (kg) post-treatment: trials that did not screen for infection
Awasthi 2000 592 10.70 (2.10) 395 10.80 (1.90) 63.7 -0.10 [ -0.35, 0.15 ]
Donnen 1998 96 9.82 (2.45) 90 9.48 (2.92) 6.7 0.34 [ -0.44, 1.12 ]
Garg 2002 166 14.35 (2.58) 181 14.11 (2.56) 13.9 0.24 [ -0.30, 0.78 ]
Hadju 1996 34 20.30 (3.20) 30 19.90 (2.20) 2.3 0.40 [ -0.93, 1.73 ]
Stephenson 1989 78 23.40 (3.80) 72 22.50 (4.41) 2.3 0.90 [ -0.42, 2.22 ]
Stephenson 1993 96 31.30 (7.45) 93 31.30 (7.71) 0.9 0.0 [ -2.16, 2.16 ]
Sur 2005 342 12.60 (5.73) 340 12.10 (4.61) 6.7 0.50 [ -0.28, 1.28 ]
Watkins 1996 116 24.36 (3.99) 110 24.93 (4.20) 3.6 -0.57 [ -1.64, 0.50 ]
Subtotal (95% CI) 1520 1311 100.0 0.04 [ -0.17, 0.24 ]
Test for heterogeneity chi-square=6.77 df=7 p=0.45 I² =0.0%
Test for overall effect z=0.35 p=0.7
02 Mean height (cm) post-treatment: trials that did not screen for infection
Awasthi 2000 592 86.23 (8.37) 395 86.21 (8.31) 48.7 0.02 [ -1.04, 1.08 ]
Donnen 1998 96 77.80 (9.40) 90 76.50 (11.80) 5.8 1.30 [ -1.78, 4.38 ]
Garg 2002 166 95.06 (8.25) 181 94.71 (8.61) 17.4 0.35 [ -1.42, 2.12 ]
Stephenson 1989 78 126.40 (7.42) 72 124.50 (8.15) 8.8 1.90 [ -0.60, 4.40 ]
Stephenson 1993 96 138.20 (9.80) 93 139.20 (11.19) 6.1 -1.00 [ -4.00, 2.00 ]
Watkins 1996 116 121.01 (7.75) 111 121.76 (7.90) 13.2 -0.75 [ -2.79, 1.29 ]
Subtotal (95% CI) 1144 942 100.0 0.15 [ -0.59, 0.89 ]
Test for heterogeneity chi-square=3.84 df=5 p=0.57 I² =0.0%
Test for overall effect z=0.40 p=0.7
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Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
03 Mean weight (kg) post-treatment: trials with adequate or unclear allocation concealment
Adams 1994 28 21.10 (2.43) 27 21.60 (3.90) 3.5 -0.50 [ -2.22, 1.22 ]
Donnen 1998 96 9.82 (2.45) 90 9.48 (2.92) 17.4 0.34 [ -0.44, 1.12 ]
Freij 1979i 6 12.30 (2.91) 7 12.10 (2.29) 1.3 0.20 [ -2.68, 3.08 ]
Garg 2002 166 14.35 (2.58) 181 14.11 (2.56) 35.8 0.24 [ -0.30, 0.78 ]
Hadju 1996 34 20.30 (3.20) 30 19.90 (2.20) 5.9 0.40 [ -0.93, 1.73 ]
Sarkar 2002 40 19.30 (6.60) 41 18.90 (5.20) 1.6 0.40 [ -2.19, 2.99 ]
Stephenson 1989 78 23.40 (3.80) 72 22.50 (4.41) 6.0 0.90 [ -0.42, 2.22 ]
Stephenson 1993 96 31.30 (7.45) 93 31.30 (7.71) 2.2 0.0 [ -2.16, 2.16 ]
Sur 2005 342 12.60 (5.73) 340 12.10 (4.61) 17.2 0.50 [ -0.28, 1.28 ]
Watkins 1996 116 24.36 (3.99) 110 24.93 (4.20) 9.2 -0.57 [ -1.64, 0.50 ]
Subtotal (95% CI) 1002 991 100.0 0.25 [ -0.08, 0.57 ]
Test for heterogeneity chi-square=4.47 df=9 p=0.88 I² =0.0%
Test for overall effect z=1.50 p=0.1
04 Mean height (cm) post-treatment: trials with adequate or unclear allocation concealment
Adams 1994 28 118.60 (6.83) 27 119.00 (7.33) 7.0 -0.40 [ -4.15, 3.35 ]
Donnen 1998 96 77.80 (9.40) 90 76.50 (11.80) 10.3 1.30 [ -1.78, 4.38 ]
Garg 2002 166 95.06 (8.25) 181 94.71 (8.61) 31.1 0.35 [ -1.42, 2.12 ]
Sarkar 2002 40 115.00 (18.90) 41 111.20 (17.60) 1.5 3.80 [ -4.16, 11.76 ]
Stephenson 1989 78 126.40 (7.42) 72 124.50 (8.15) 15.6 1.90 [ -0.60, 4.40 ]
Stephenson 1993 96 138.20 (9.80) 93 139.20 (11.19) 10.9 -1.00 [ -4.00, 2.00 ]
Watkins 1996 116 121.01 (7.75) 111 121.76 (7.90) 23.6 -0.75 [ -2.79, 1.29 ]
Subtotal (95% CI) 620 615 100.0 0.29 [ -0.70, 1.27 ]
Test for heterogeneity chi-square=4.60 df=6 p=0.60 I² =0.0%
Test for overall effect z=0.57 p=0.6
05 Mean mid upper arm circumference (cm): trials that did not screen for infection
Donnen 1998 96 13.50 (1.40) 90 13.40 (1.40) 28.0 0.10 [ -0.30, 0.50 ]
Stephenson 1989 78 16.70 (1.41) 72 16.30 (1.53) 20.4 0.40 [ -0.07, 0.87 ]
Stephenson 1993 96 18.40 (1.96) 93 18.00 (2.12) 13.4 0.40 [ -0.18, 0.98 ]
Watkins 1996 116 18.67 (1.34) 111 18.79 (1.31) 38.2 -0.12 [ -0.46, 0.22 ]
Subtotal (95% CI) 386 366 100.0 0.12 [ -0.10, 0.33 ]
Test for heterogeneity chi-square=4.11 df=3 p=0.25 I² =27.0%
Test for overall effect z=1.08 p=0.3
06 Mean triceps skin fold (mm): trials that did not screen for infection [random]
Stephenson 1989 78 7.70 (1.94) 72 7.60 (2.04) 57.7 0.10 [ -0.54, 0.74 ]
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Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Stephenson 1993 96 9.10 (2.73) 93 7.30 (2.50) 42.3 1.80 [ 1.05, 2.55 ]
Subtotal (95% CI) 174 165 100.0 0.82 [ 0.33, 1.30 ]
Test for heterogeneity chi-square=11.52 df=1 p=0.0007 I² =91.3%
Test for overall effect z=3.31 p=0.0009
07 Mean subscapular skin fold (mm): trials that did not screen for infection [random]
Stephenson 1989 78 5.70 (1.32) 72 5.40 (1.19) 65.6 0.30 [ -0.10, 0.70 ]
Stephenson 1993 96 6.80 (1.96) 93 5.40 (1.93) 34.4 1.40 [ 0.85, 1.95 ]
Subtotal (95% CI) 174 165 100.0 0.68 [ 0.35, 1.00 ]
Test for heterogeneity chi-square=9.91 df=1 p=0.002 I² =89.9%
Test for overall effect z=4.09 p=0.00004
08 Mean haemoglobin (g/L) levels post-treatment: trials that did not screen for infection
Garg 2002 166 117.80 (14.17) 181 117.40 (13.45) 45.1 0.40 [ -2.51, 3.31 ]
Palupi 1997 95 120.10 (9.70) 96 118.60 (11.40) 42.5 1.50 [ -1.50, 4.50 ]
Stephenson 1993 27 119.00 (10.39) 26 114.00 (10.20) 12.4 5.00 [ -0.54, 10.54 ]
Subtotal (95% CI) 288 303 100.0 1.44 [ -0.52, 3.40 ]
Test for heterogeneity chi-square=2.08 df=2 p=0.35 I² =3.6%
Test for overall effect z=1.44 p=0.1
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Analysis 08.03. Comparison 08 Subgroup and sensitivity analyses, Outcome 03 Multiple dose < 1 year: change
in value
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 08 Subgroup and sensitivity analyses
Outcome: 03 Multiple dose < 1 year: change in value
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Weight (kg): trials with adequate or unclear allocation concealment [random]
Donnen 1998 100 1.64 (1.12) 98 2.09 (1.19) 19.6 -0.45 [ -0.77, -0.13 ]
Dossa 2001 37 1.20 (1.00) 28 1.20 (1.10) 7.5 0.0 [ -0.52, 0.52 ]
Kruger 1996 37 2.32 (0.64) 37 2.70 (1.22) 10.3 -0.38 [ -0.82, 0.06 ]
Stephenson 1993 95 3.10 (1.36) 93 2.20 (1.16) 15.6 0.90 [ 0.54, 1.26 ]
Watkins 1996 116 1.82 (0.86) 110 1.69 (0.73) 47.1 0.13 [ -0.08, 0.34 ]
Subtotal (95% CI) 385 366 100.0 0.07 [ -0.07, 0.22 ]
Test for heterogeneity chi-square=34.65 df=4 p=<0.0001 I² =88.5%
Test for overall effect z=1.02 p=0.3
02 Height (cm): trials with adequate or unclear allocation concealment
Donnen 1998 100 7.27 (3.56) 98 8.46 (4.18) 1.9 -1.19 [ -2.27, -0.11 ]
Dossa 2001 37 6.50 (2.60) 28 6.00 (2.50) 1.5 0.50 [ -0.75, 1.75 ]
Kruger 1996 37 5.62 (0.90) 37 5.54 (0.91) 13.3 0.08 [ -0.33, 0.49 ]
Stephenson 1993 95 3.60 (1.07) 93 3.70 (1.16) 22.2 -0.10 [ -0.42, 0.22 ]
Watkins 1996 116 2.45 (0.75) 111 2.39 (0.73) 61.1 0.06 [ -0.13, 0.25 ]
Subtotal (95% CI) 385 367 100.0 0.01 [ -0.14, 0.16 ]
Test for heterogeneity chi-square=6.14 df=4 p=0.19 I² =34.8%
Test for overall effect z=0.12 p=0.9
-10.0 -5.0 0 5.0 10.0
Favours control Favours deworming
89Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Analysis 08.04. Comparison 08 Subgroup and sensitivity analyses, Outcome 04 Multiple dose < 1 year: end
value
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 08 Subgroup and sensitivity analyses
Outcome: 04 Multiple dose < 1 year: end value
Study Deworming Control Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Mean weight (kg): trials with adequate or unclear allocation concealment
Donnen 1998 96 10.99 (2.32) 90 10.98 (2.69) 46.5 0.01 [ -0.71, 0.73 ]
Stephenson 1993 95 31.90 (7.99) 93 31.30 (7.17) 5.2 0.60 [ -1.57, 2.77 ]
Sur 2005 342 12.90 (7.40) 340 12.40 (4.61) 28.5 0.50 [ -0.42, 1.42 ]
Watkins 1996 116 25.19 (4.20) 110 25.63 (4.30) 19.8 -0.44 [ -1.55, 0.67 ]
Subtotal (95% CI) 649 633 100.0 0.09 [ -0.40, 0.58 ]
Test for heterogeneity chi-square=1.89 df=3 p=0.60 I² =0.0%
Test for overall effect z=0.36 p=0.7
02 Mean height (cm): trials with adequate or unclear allocation concealment
Donnen 1998 96 83.20 (8.60) 90 82.40 (10.00) 29.2 0.80 [ -1.89, 3.49 ]
Stephenson 1993 95 138.40 (11.11) 93 139.20 (11.19) 20.7 -0.80 [ -3.99, 2.39 ]
Watkins 1996 116 122.03 (7.75) 111 122.78 (8.00) 50.1 -0.75 [ -2.80, 1.30 ]
Subtotal (95% CI) 307 294 100.0 -0.31 [ -1.76, 1.14 ]
Test for heterogeneity chi-square=0.92 df=2 p=0.63 I² =0.0%
Test for overall effect z=0.42 p=0.7
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Analysis 08.05. Comparison 08 Subgroup and sensitivity analyses, Outcome 05 Multiple dose > 1 year: change
in value
Review: Deworming drugs for treating soil-transmitted intestinal worms in children: effects on growth and school performance
Comparison: 08 Subgroup and sensitivity analyses
Outcome: 05 Multiple dose > 1 year: change in value
Study Deworming Control Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Mean change in weight (kg): trials with adequate or unclear allocation concealment
Awasthi 1995 25 4.60 (0.55) 25 3.36 (0.60) 53.2 1.24 [ 0.92, 1.56 ]
Awasthi 2001 63 3.22 (2.03) 61 3.05 (1.47) 46.8 0.17 [ -0.45, 0.79 ]
Subtotal (95% CI) 88 86 100.0 0.74 [ -0.31, 1.79 ]
Test for heterogeneity chi-square=8.99 df=1 p=0.003 I² =88.9%
Test for overall effect z=1.39 p=0.2
02 Mean change in height (cm): trials with adequate or unclear allocation concealment
Awasthi 1995 25 17.59 (4.50) 25 16.40 (4.00) 48.4 1.19 [ -1.17, 3.55 ]
Awasthi 2001 63 16.50 (6.51) 61 16.10 (6.48) 51.6 0.40 [ -1.89, 2.69 ]
Subtotal (95% CI) 88 86 100.0 0.78 [ -0.86, 2.42 ]
Test for heterogeneity chi-square=0.22 df=1 p=0.64 I² =0.0%
Test for overall effect z=0.93 p=0.4
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Comparison: 08 Subgroup and sensitivity analyses
Outcome: 06 Multiple dose > 1 year: end value
Study Deworming Control Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
01 Mean weight (kg): trials with adequate or unclear allocation concealment
Awasthi 2001 63 9.94 (0.16) 61 9.87 (0.16) 0.07 [ 0.01, 0.13 ]
02 Mean height (cm): trials with adequate or unclear allocation concealment
Awasthi 2001 63 81.75 (3.96) 61 81.60 (3.91) 0.15 [ -1.24, 1.54 ]
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